Tokushima University / Educator and Researcher Directory --- Wada, Yuuma

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Yosuke Iwakawa, Kouzou Yoshikawa, Koichi Okamoto, Tetsuji Takayama, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Mitsuo Shimada : Four cases of gastric adenocarcinoma and proximal polyposis of the stomach treated by robotic total gastrectomy, Surgical Case Reports, Vol.8, No.1, 70, 2022. (Summary) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is a rare disease and characterized by a unique point mutation in the promoter 1B region of the adenomatous polyposis coli (APC) gene. There are two aims in surgery for GAPPS; the first is prophylactic gastrectomy, and the second is excising concurrent cancer. We performed robotic total gastrectomy (RTG) for four cases of GAPPS. Case 1 was a woman in her 40 s whose sister had died from gastric cancer. Mutational analysis revealed mutation of APC exon 1B. We performed prophylactic gastrectomy. Case 2 was a woman in her 30 s who had a mutation of APC exon 1B, and preoperative biopsy revealed suspected adenocarcinoma. Case 3 was a woman in her 40 s who was diagnosed with gastric cancer with multiple polyps in the stomach and a mutation of APC exon 1B. Case 4 was a woman in her 20 s in whom biopsy revealed low-grade dysplasia of a raised lesion. She had a mutation in APC exon 1B. We performed RTG with D1 + lymphadenectomy in all patients, and there were no intraoperative complications. Patients with GAPPS are mainly followed regularly with repeat biopsy, and tumors are detected in an early stage. As the safety of robotic surgery for the early gastric cancer is reported, RTG is an option for these patients. This is the first report of RTG for GAPPS patients. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-022-01425-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35435526 ● Search Scopus @ Elsevier (PMID): 35435526 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-022-01425-6 (DOI: 10.1186/s40792-022-01425-6, PubMed: 35435526)

Academic Paper (Unrefereed Paper):

1.	Chie Takasu, Masaaki Nishi, Kozo Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : Preoperative evaluation to determine the difficulty of No. 6 lymphadenectomy in laparoscopic gastrectomy., BMC surgery, Vol.24, No.1, 69, 2024. (Summary) Laparoscopic gastrectomy (LG) requires a long learning curve because of the complicated surgical procedures. Infrapyloric (No. 6) lymph node dissection (LND) is one of the difficult procedures in LG, especially for trainees. This study investigated the impact of the prediction of the difficulty of No. 6 LND. We retrospectively reviewed the preoperative computed tomography (CT) images and individual operative video records of 57 patients who underwent LG with No. 6 LND to define and predict the No. 6 LND difficulty. To evaluate whether prediction of the difficulty of No. 6 LND could improve surgical outcomes, 48 patients who underwent laparoscopic distal gastrectomy were assessed (30 patients without prediction by a qualified surgeon and 18 patients with prediction by a trainee). The anatomical characteristic that LND required > 2 cm of dissection along the right gastroepiploic vein was defined as difficulty of No. 6 LND. Of the 57 LG patients, difficulty was identified intraoperatively in 21 patients (36.8%). Among the several evaluated anatomical parameters, the length between the right gastroepiploic vein and the right gastroepiploic artery in the maximum intensity projection in contrast-enhanced CT images was significantly correlated with the intraoperative difficulty of No. 6 LND (p < 0.0001). Surgical outcomes, namely intraoperative minor bleeding, postoperative pancreatic fistula, and drain amylase concentration were not significantly different between LG performed by a trainee with prediction compared with that by a specialist without prediction. Preoperative evaluation of the difficulty of No. 6 LND is useful for trainees, to improve surgical outcomes. (Keyword) Humans / Retrospective Studies / Stomach Neoplasms / Lymph Node Excision / Laparoscopy / Gastrectomy / Postoperative Complications (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-024-02349-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38389108 ● Search Scopus @ Elsevier (PMID): 38389108 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-024-02349-8 (DOI: 10.1186/s12893-024-02349-8, PubMed: 38389108)
2.	Chie Takasu, Yuji Morine, Kozo Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : Role of stromal PD-L1 expression in colorectal liver metastasis., BMC cancer, Vol.24, No.1, 97, 2024. (Summary) The outcomes of immune checkpoint blockade for colorectal cancer (CRC) treatment are unsatisfactory. Furthermore, the efficacy of immune checkpoint blockade for liver metastasis of various cancer is poor. Here, we investigated the relationship between stromal programmed death-ligand 1 (PD-L1) expression and the prognosis of patients with colorectal cancer liver metastasis (CRLM). The present study enrolled 84 CRLM patients who underwent surgery (R0) for CRC. Immunohistochemistry was performed to analyze stromal PD-L1 expression in CRLM. Stromal PD-L1 was expressed in 52.3% of CRLM samples, which was associated with fewer not optimally resectable metastases (p = 0.04). Stromal PD-L1 also tended to associate with a lower tumor grade (p = 0.08). Stromal PD-L1-positive patients had longer overall survival (p = 0.003). Multivariate analysis identified stromal PD-L1 expression (p = 0.008) and poorer differentiation (p < 0.001) as independent prognostic indicators. Furthermore, stromal PD-L1 expression was correlated to a high number of tumor-infiltrating lymphocytes (TILs). Stromal PD-L1- and low TIL groups had shorter OS than stromal PD-L1 + and high TIL groups (46.6% vs. 81.8%, p = 0.05) Stromal PD-L1-positive patients had longer disease-free survival (DFS) (p = 0.03) and time to surgical failure (p = 0.001). Interestingly, stromal PD-L1 expression was positively related to the desmoplastic subtype (p = 0.0002) and inversely related to the replacement subtype of the histological growth pattern (p = 0.008). Stromal PD-L1 expression may be a significant prognostic marker for CRLM. (Keyword) Humans / B7-H1 Antigen / Colorectal Neoplasms / Immune Checkpoint Inhibitors / Liver Neoplasms / Lymphocytes, Tumor-Infiltrating / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1186/s12885-024-11869-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38233811 ● Search Scopus @ Elsevier (PMID): 38233811 ● Search Scopus @ Elsevier (DOI): 10.1186/s12885-024-11869-8 (DOI: 10.1186/s12885-024-11869-8, PubMed: 38233811)
3.	Takayuki Noma, Masaaki Nishi, Chie Takasu, Yuuma Wada, Kozo Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Yuko Miyakami, Kengo Atsumi, Hisanori Uehara and Mitsuo Shimada : Conversion surgery after successful response to chemotherapy (S-1 + oxaliplatin + nivolumab) in a patient with stage IV gastric cancer with peritoneal metastasis (P1, CY1): a case report., International cancer conference journal, Vol.13, No.1, 11-16, 2023. (Summary) We here present a case report of a patient with Stage IV gastric cancer with peritoneal metastasis (P1, CY1) who underwent conversion surgery after a successful response to chemotherapy (S-1 + oxaliplatin + nivolumab). The patient was a woman in her 60 s. Her chief complaint was epigastric pain. Upper gastrointestinal endoscopy showed Type 4 advanced carcinoma on the lesser curvature of the gastric body. Biopsy showed Group 5 (poorly differentiated adenocarcinoma) and HER2 was negative. Staging laparoscopy revealed seeding in the round ligament of the liver (P1) and adenocarcinoma cells in ascites (CY1). Ten courses of chemotherapy (S-1 + oxaliplatin + nivolumab) were administered, after which contrast-enhanced computed tomography showed that the primary tumor had shrunk and seeding was no longer detectable. Upper gastrointestinal endoscopy revealed scar-like changes. A second staging laparoscopy revealed that ascites cytology was negative and a biopsy of the round ligament of the liver showed no malignant cells (P0, CY0). Conversion surgery comprising laparoscopic total gastrectomy with D2 lymph node dissection and resection of the round ligament of the liver was performed. The postoperative course was uneventful. Histopathological examination of the resected specimen revealed no tumor cells in the gastric mesentery or the round ligament of the liver. The pathological diagnosis was gastric cancer [M, U, L, Less, Ant, Post, type4, T3(SS), N0, M0 (H0, P0, CY0), ypStage IIA]. Adjuvant chemotherapy (S-1) was commenced. The patient is still alive 7 months later with no evidence of recurrence. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13691-023-00628-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38187176 ● Search Scopus @ Elsevier (PMID): 38187176 ● Search Scopus @ Elsevier (DOI): 10.1007/s13691-023-00628-4 (DOI: 10.1007/s13691-023-00628-4, PubMed: 38187176)
4.	Masaaki Nishi, Yuuma Wada, Kozo Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Utility of robotic surgery for Siewert type II/III adenocarcinoma of esophagogastric junction: transhiatal robotic versus laparoscopic approach., BMC Surgery, Vol.23, No.1, 128, 2023. (Summary) Robotic surgery (RS) has been rapidly adopted for gastric cancer and adenocarcinoma of the esophagogastric junction (AEG). However, the utility of RS for Siewert type II/III AEG remains unclear. Forty-one patients who underwent either transhiatal RS (n = 15) or laparoscopic surgery (LS) (n = 26) for Siewert type II/III AEG were enrolled in this study. The surgical outcomes of the two groups were compared. In the entire cohort, there were no significant intergroup differences in the operative time, blood loss volume, or number of retrieved lymph nodes. The length of the postoperative hospital stay was shorter in the RS group than in the LS group (14.20 ± 7.10 days vs. 18.73 ± 17.82 days, respectively; p = 0.0388). The morbidity rate (Clavien-Dindo grade ≥ 2) was similar between the groups. In the Siewert II cohort, there were no significant intergroup differences in short-term outcomes. In the entire cohort, there was no significant difference between the RS and LS groups in the 3-year overall survival rate (91.67% vs. 91.48%, N.S.) or 3-year disease-free survival rate (91.67% vs. 91.78%, N.S.), respectively. Likewise, in the Siewert type II cohort, there was no significant difference between the RS and LS groups in the 3-year overall survival rate (80.00% vs. 93.33%, N.S.) or 3-year disease-free survival rate (80.00% vs. 94.12%, N.S.), respectively. Transhiatal RS for Siewert II/III AEG was safe and contributed to similar short-term and long-term outcomes compared with LS. (Keyword) Humans / Robotic Surgical Procedures / Retrospective Studies / Gastrectomy / Adenocarcinoma / Stomach Neoplasms / Laparoscopy / Esophagogastric Junction / Esophageal Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-023-02045-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37194030 ● Search Scopus @ Elsevier (PMID): 37194030 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-023-02045-z (DOI: 10.1186/s12893-023-02045-z, PubMed: 37194030)
5.	Toshiaki Yoshimoto, Kozo Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Takayuki Noma and Mitsuo Shimada : Surgical Outcomes of Gastrectomy in Hemodialysis Patients with Gastric Cancer., The American surgeon, Vol.89, No.12, 6328-6330, 2023. (Keyword) Humans / Stomach Neoplasms / Retrospective Studies / Laparoscopy / Gastrectomy / Treatment Outcome / Renal Dialysis (Link to Publication Site) ● Publication site (DOI): 10.1177/00031348231173970 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37132264 ● Search Scopus @ Elsevier (PMID): 37132264 ● Search Scopus @ Elsevier (DOI): 10.1177/00031348231173970 (DOI: 10.1177/00031348231173970, PubMed: 37132264)
6.	Takuya Tokunaga, Maki Sugimoto, Yu Saitou, Hideya Kashihara, Kozo Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Yuhei Waki, Toshiaki Yoshimoto, Takayuki Noma and Mitsuo Shimada : Transanal lateral lymph node dissection with intraoperative hologram support in low rectal cancer., Surgical endoscopy, Vol.37, No.7, 5414-5420, 2023. (Summary) In Japan, the standard treatment for stage II/III advanced low rectal cancer is total mesorectal excision plus lateral lymph node dissection (LLND). There are also recent reports on the use of transanal LLND. However, the transanal anatomy is difficult to understand, and additional support tools are required to improve the surgical safety. The present study examined the utility of holograms with mixed reality as an intraoperative support tool for assessing the complex pelvic anatomy. Polygon (stereolithography) files of patients' pelvic organs were created and exported from the SYNAPSE VINCENT imaging system and uploaded into the Holoeyes MD virtual reality software. Three-dimensional images were automatically converted into patient-specific holograms. Each hologram was then installed into a head mount display (HoloLens2), and the surgeons and assistants wore the HoloLens2 when they performed transanal LLND. Twelve digestive surgeons with prior practice in hologram manipulation evaluated the utility of the intraoperative hologram support by means of a questionnaire. Intraoperative hologram support improved the surgical understanding of the lateral lymph node region anatomy. In the questionnaire, 75% of the surgeons answered that the hologram accurately reflected the anatomy, and 92% of the surgeons answered that the anatomy was better understood by simulating the hologram intraoperatively than preoperatively. Moreover, 92% of the surgeons agreed that intraoperative holograms were a useful support tool for improving the surgical safety. Intraoperative hologram support improved the surgical understanding of the pelvic anatomy for transanal LLND. Intraoperative holograms may represent a next-generation surgical tool for transanal LLND. (Keyword) Humans / Treatment Outcome / Lymph Node Excision / Lymph Nodes / Rectal Neoplasms / Dissection (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-023-09977-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37017769 ● Search Scopus @ Elsevier (PMID): 37017769 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-023-09977-w (DOI: 10.1007/s00464-023-09977-w, PubMed: 37017769)
7.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : Stapler insertion angle toward the esophagus reduces the incidence of early postoperative Roux stasis syndrome after distal gastrectomy in minimally invasive surgery., BMC Surgery, Vol.23, No.1, 54, 2023. (Summary) Roux stasis syndrome (RSS) after Roux-en-Y (RY) reconstruction significantly prolongs the hospital stay and decreases the quality of life. The purpose of the present study was to evaluate the incidence of RSS in patients who underwent distal gastrectomy for gastric cancer and to identify the factors related to the development of RSS after mechanical RY reconstruction in minimally invasive surgery (MIS). This study included 134 patients who underwent distal gastrectomy in MIS with mechanical RY anastomosis. RSS was defined as the presence of symptoms such as nausea, vomiting, or abdominal fullness, and the confirmation of delayed gastric emptying on imaging or gastrointestinal fiber testing. Clinical data were checked, including body mass index, operative procedure, age, sex, operative time, blood loss volume, extent of lymph node dissection, final stage, stapler insertion angle, method of entry hole closure. The relationship between the incidence of RSS and these factors was analyzed. RSS occurred in 24 of 134 patients (17.9%). RSS occurred significantly more frequently in patients with D2 lymphadenectomy than in patients with D1 + lymphadenectomy (p = 0.04). All patients underwent side-to-side anastomosis via the antecolic route. The incidence of RSS was significantly greater in patients with a stapler insertion angle toward the greater curvature (n = 20, 22.5%) versus the esophagus (n = 4, 8.9%) (p = 0.04). The multivariate logistic regression model revealed that the stapler insertion angle to the greater curvature is identified as independent risk factor for RSS (OR 3.23, 95%Cl 1.01-10.3, p = 0.04). Stapler insertion angle toward the esophagus may reduce the incidence of early postoperative RSS rather than toward the greater curvature. (Keyword) Humans / Incidence / Quality of Life / Gastrectomy / Anastomosis, Roux-en-Y / Esophagus / Stomach Neoplasms / Minimally Invasive Surgical Procedures / Postoperative Complications (Tokushima University Institutional Repository) ● Metadata: 118879 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-023-01954-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36906525 ● Search Scopus @ Elsevier (PMID): 36906525 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-023-01954-3 (Tokushima University Institutional Repository: 118879, DOI: 10.1186/s12893-023-01954-3, PubMed: 36906525)
8.	Katsuki Miyazaki, Yuji Morine, Caiming Xu, Chiharu Nakasu, Yuuma Wada, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Mitsuo Shimada and Ajay Goel : Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma., Cells, Vol.12, No.4, 2023. (Summary) Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients with HCC. Recent evidence suggests that epidermal growth factor receptor (EGFR) activation can trigger Lenvatinib-resistance; and is considered an important therapeutic target in HCC. Curcumin, one of the most studied naturally occurring botanicals with robust anti-cancer activity, is also reported to be a potent tyrosine kinase inhibitor. In this study, we hypothesized that the anti-EGFR potential of Curcumin might help overcome Lenvatinib resistance in HCC. We established two Lenvatinib-resistant cells and discovered that a combination of Curcumin and Lenvatinib exhibited a synergistic anti-tumor efficacy in the resistant HCC cell lines. In line with previous reports, Lenvatinib-resistant cell lines revealed significant activation of the EGFR, and genomewide transcriptomic profiling analysis identified that the PI3K-AKT pathway was associated with Lenvatinib resistance. The combination treatment with Curcumin and Lenvatinib dramatically suppressed gene and protein expression of the EGFR-PI3K-AKT pathway, suggesting Curcumin overcomes Lenvatinib resistance via inhibition of EGFR. We further validated these findings in tumor spheroids derived from resistant cell lines. In conclusion, we, for the first time, report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Curcumin / Liver Neoplasms / Proto-Oncogene Proteins c-akt / Phosphatidylinositol 3-Kinases / Cell Line, Tumor / Signal Transduction / Protein Kinase Inhibitors / ErbB Receptors (Tokushima University Institutional Repository) ● Metadata: 118580 (Link to Publication Site) ● Publication site (DOI): 10.3390/cells12040612 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36831279 ● Search Scopus @ Elsevier (PMID): 36831279 ● Search Scopus @ Elsevier (DOI): 10.3390/cells12040612 (Tokushima University Institutional Repository: 118580, DOI: 10.3390/cells12040612, PubMed: 36831279)
9.	Katsuki Miyazaki, Yuuma Wada, Keisuke Okuno, Tatsuro Murano, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroaki Ikematsu, Yusuke Kinugasa, Mitsuo Shimada and Ajay Goel : An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer., Molecular Cancer, Vol.22, No.1, 2, 2023. (Summary) According to current guidelines, more than 70% of patients with invasive submucosal colorectal cancer (T1 CRC) undergo a radical operation with lymph node dissection, even though only ~ 10% have lymph node metastasis (LNM). Hence, there is imperative to develop biomarkers that can help robustly identify LNM-positive patients to prevent such overtreatments. Given the emerging interest in exosomal cargo as a source for biomarker development in cancer, we examined the potential of exosomal miRNAs as LNM prediction biomarkers in T1 CRC. We analyzed 200 patients with high-risk T1 CRC from two independent cohorts, including a training (n = 58) and a validation cohort (n = 142). Cell-free and exosomal RNAs from pre-operative serum were extracted, followed by quantitative reverse-transcription polymerase chain reactions for a panel of miRNAs. A panel of four miRNAs (miR-181b, miR-193b, miR-195, and miR-411) exhibited robust ability for detecting LNM in the exosomal vs. cell-free component. We subsequently established a cell-free and exosomal combination signature, successfully validated in two independent clinical cohorts (AUC, 0.84; 95% CI 0.70-0.98). Finally, we developed a risk-stratification model by including key pathological features, which reduced the false positive rates for LNM by 76% without missing any true LNM-positive patients. Our novel exosomal miRNA-based liquid biopsy signature robustly identifies T1 CRC patients at risk of LNM in a preoperative setting. This could be clinically transformative in reducing the significant overtreatment burden of this malignancy. (Keyword) Humans / Lymphatic Metastasis / Exosomes / Colorectal Neoplasms / Biomarkers, Tumor / MicroRNAs / Liquid Biopsy (Tokushima University Institutional Repository) ● Metadata: 118926 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12943-022-01685-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36609320 ● Search Scopus @ Elsevier (PMID): 36609320 ● Search Scopus @ Elsevier (DOI): 10.1186/s12943-022-01685-8 (Tokushima University Institutional Repository: 118926, DOI: 10.1186/s12943-022-01685-8, PubMed: 36609320)
10.	Hideya Kashihara, Mitsuo Shimada, Kozo Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : The Impact of the Pre-operative Neutrophil-lymphocyte Ratio as the Predictive Marker of Post-operative Weight Loss and Improving Diabetes in Sleeve Gastrectomy., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 140-144, 2023. (Summary) The aim was to investigate the impact of the neutrophil-lymphocyte ratio (NLR) in sleeve gastrectomy (SG). 15 obese patients were enrolled in this study ; mean body weight (BW) 127.5kg ; mean body mass index (BMI) 46.7kg/m. 10 of these were diabetics who underwent a SG. The impact of the pre-operative NLR on the percentage of excess weight loss (%EWL) and remission of diabetes 1 year post-operative were examined. The %EWL at 1 year post-operative were 46.3%. Improvements were also evident in the diabetes at 1 year post-operative : complete remission (CR) 40%, partial remission (PR) 20% and Improve 40%. Comparing pre-operative NLR in %EWL<50% and ≧50% in 1 year post-operative, <50% was 2.64 and ≧50% was 2.03. The NLR in CR and PR was significantly lower than that in Improve. The pre-operative NLR may be a predictive marker of weight loss and improving diabetes after SG. J. Med. Invest. 70 : 140-144, February, 2023. (Keyword) Humans / Obesity, Morbid / Treatment Outcome / Neutrophils / Retrospective Studies / Laparoscopy / Diabetes Mellitus / Weight Loss / Body Mass Index / Gastrectomy (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.140 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164710 ● Search Scopus @ Elsevier (PMID): 37164710 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.140 (DOI: 10.2152/jmi.70.140, PubMed: 37164710)
11.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shohei Okikawa, Shoko Yamashita and Mitsuo Shimada : Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy., BMC Cancer, Vol.22, No.1, 1263, 2022. (Summary) The role of the immune system in locally advanced rectal cancer (LARC) following preoperative chemoradiotherapy (CRT) has been widely investigated in recent years. This study examined the prognostic significance of indoleamine-pyrrole 2,3-dioxygenase (IDO) expression in patients with LARC who received preoperative CRT. Ninety patients with LARC who underwent preoperative CRT and curative resection were enrolled. IDO and programmed death-ligand 1 (PD-L1) expression was evaluated by immunohistochemistry. Clinicopathological factors did not significantly differ between patients with positive or negative IDO expression, excluding the correlation of positive IDO expression with better tumor differentiation (p = 0.02). IDO expression was not associated with pathological response (p = 0.44), but it was associated with PD-L1 expression. The 5-year overall survival (OS) rate was significantly worse in the IDO-positive group than in the IDO-negative group (64.8% vs. 85.4%, p = 0.02). Univariate analysis identified IDO and PD-L1 expression (p = 0.02), surgical procedure (p = 0.01), final pathological stage (p = 0.003), lymph node metastasis (p < 0.001), and lymphatic invasion (p = 0.002) as significant prognostic factors for OS. Multivariate analysis revealed that IDO expression (HR: 7.10, p = 0.0006), surgical procedure (HR: 5.03, p = 0.01), lymph node metastasis (HR: 2.37, p = 0.04) and lymphatic invasion (HR: 4.97, p = 0.01) were independent prognostic indicators. Disease-free survival was not correlated with IDO or PD-L1 expression. IDO expression in patients with LARC who received preoperative CRT could be a potential prognostic indicator. IDO expression could be a useful marker for specifying individual treatment strategies in LARC. (Keyword) Humans / B7-H1 Antigen / Chemoradiotherapy / Lymphatic Metastasis / Neoadjuvant Therapy / Prognosis / Rectal Neoplasms / Indoleamine-Pyrrole 2,3,-Dioxygenase (Tokushima University Institutional Repository) ● Metadata: 118002 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12885-022-10357-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36471264 ● Search Scopus @ Elsevier (PMID): 36471264 ● Search Scopus @ Elsevier (DOI): 10.1186/s12885-022-10357-1 (Tokushima University Institutional Repository: 118002, DOI: 10.1186/s12885-022-10357-1, PubMed: 36471264)
12.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Visualization of the pelvic nerves using magnetic resonance imaging for rectal cancer surgery., Surgical Endoscopy, 2022. (Summary) This study evaluated the visualization of the pelvic nerves using magnetic resonance imaging (MRI) combined with computed tomography (CT) to synthesize three-dimensional (3D) reconstruction images of the pelvic organs. The CT and MRI scans were performed for patients with rectal cancer who underwent surgery. The out-of-phase image of LAVA-Flex was used to identify the pelvic nerves. The images of the pelvic nerves were extracted from the MRI scans, and those of the arteries and rectum and pelvis were extracted from the CT scans. Each extracted organ image was used to synthesize 3D reconstruction images. The MRI scan allowed adequate visualization of the pelvic splanchnic nerves, inferior hypogastric plexus, and obturator nerves. The comparison of 3D reconstruction images and intraoperative findings showed matched images. We visualized the pelvic nerves using MRI and synthesized 3D reconstruction images of the pelvic organs. Preoperative confirmation of the location of the pelvic organs is important to prevent unanticipated injury during rectal cancer surgery. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-022-09771-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36418640 ● Search Scopus @ Elsevier (PMID): 36418640 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-022-09771-0 (DOI: 10.1007/s00464-022-09771-0, PubMed: 36418640)
13.	Chie Takasu, 調憲, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : オンライン時代は女性医師キャリア形成の追い風となる, The Japanese Journal of Gastroenterological Surgery, Vol.55, No.11, 729-732, 2022. (Summary) 新型コロナウイルス感染症の拡大が,これまで停滞していた医師の働き方改革の推進へとつながっている.その中でも,学会のオンライン化は医師の働き方に大きな変化をもたらした.学会のリモート参加は,自宅に居ながら参加でき,地方からも参加しやすく,移動時間と費用の大きな削減となる.オンデマンド配信は,時間・場所にかかわらず学ぶ機会を得られる非常に有効なツールとなる.また,学会の委員活動など,習慣的に行われていた対面での会議が,現在はほぼ遠隔で行われている.これまで時間的制約により,積極的に学会活動に手を挙げることができなかった女性医師の同分野での活躍推進が期待される.特に子育て中の女性医師にとって,オンライン化はワーク・ライフ・バランスを維持しながらキャリアを形成していく有効なツールとなりうる.この変化を逃さず女性活躍推進へとつなげるための,オンライン学会(ハイブリット形式)の継続を強く要望したい.(著者抄録) (Keyword) 育児労働衛生女性医師抄録作成と索引作成職歴の移動テレビ会議テレワーキングヒト女 (Link to Publication Site) ● Publication site (DOI): 10.5833/jjgs.2022.sr005 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390857226420483072 ● Search Scopus @ Elsevier (DOI): 10.5833/jjgs.2022.sr005 (DOI: 10.5833/jjgs.2022.sr005, CiNii: 1390857226420483072)
14.	Yosuke Iwakawa, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Chie Takasu, Mitsuo Shimada, Yasuyo Saijo, Minoru Matsumoto, Takeshi Oya and Hisanori Uehara : Pleomorphic type undifferentiated gastric sarcoma, report of a case., Clinical Journal of Gastroenterology, Vol.16, No.1, 20-25, 2022. (Summary) Reports on pleomorphic type of undifferentiated sarcoma (PUS) originating from the gastrointestinal tract, especially the stomach, are extremely rare. We herein report a case of pleomorphic type undifferentiated gastric sarcoma. The patient was a 67-year-old woman. The chief complaint was upper abdominal pain. Upper gastrointestinal endoscopy, ultrasonography, and contrast-enhanced computed tomography showed two submucosal tumors at the greater curvature of the fundus and the lesser curvature of the gastric angle. Endoscopic ultrasound-guided fine-needle aspiration revealed a c-kit-negative spindle cell tumor at the greater curvature of the fundus. Total gastrectomy, splenectomy, and partial resection of the diaphragm and liver were performed. One lesion had invaded the lateral segment of the liver, left diaphragm and spleen. The postoperative course was uneventful. Histopathological and immunohistochemical examinations of the resected specimen revealed PUS. Peritoneal dissemination was detected at 8 months after surgery. However, no effective therapeutic agents were adopted for chemotherapy. The patient had poor performance status due to disease progression and underwent best supportive care. The patient died 10 months after surgery. This case highlights the imaging, histological diagnosis, and treatment strategy for PUS originating from the stomach. Surgeons should be aware of PUS as a differential diagnosis in cases with submucosal tumor of the stomach. (Keyword) Female / Humans / Aged / Stomach Neoplasms / Gastrectomy / Sarcoma / Endoscopy, Digestive System / Liver Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-022-01729-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36289170 ● Search Scopus @ Elsevier (PMID): 36289170 ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-022-01729-y (DOI: 10.1007/s12328-022-01729-y, PubMed: 36289170)
15.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in gastric cancer., Oncology Letters, Vol.24, No.5, 415, 2022. (Summary) Previous studies have revealed the usefulness of neoadjuvant chemotherapy (NAC) followed by surgery for clinical stage III gastric cancer (GC). The tumor volume at the primary tumor site (PT) is sometimes difficult to measure because of the luminal structure; therefore, evaluation of the lymph node (LN) response to NAC may help to more accurately predict survival outcomes. The present study therefore evaluated the LN response to NAC for prediction of survival outcomes in patients with GC. The study involved 160 patients with clinical stage III GC who underwent NAC (n=14) and upfront surgery (n=146). PT and LN responses to NAC were evaluated, various clinicopathological factors were evaluated and Cox proportional hazard regression analyses were performed to determine survival outcomes. Overall survival (OS) and disease-free survival (DFS) were not significantly different between patients who underwent NAC and those who underwent upfront surgery (OS, P=0.71; DFS, P=0.50). However, although there were no significant differences in PT responses, patients classified as LN non-responders to NAC had a significantly worse prognosis compared with patients classified as LN responders in terms of DFS (PT, P=0.93; LN, P<0.01) and OS (PT, P=0.84; LN, P<0.01). Moreover, a higher neutrophil-lymphocyte ratio tended to be associated with poor DFS [univariate: hazard ratio (HR)=4.23, P=0.06; multivariate: HR=6.45, P=0.04]. Finally, an LN response to NAC was significantly better for prediction of recurrence (univariate, HR=7.79, 95% confidence interval=1.16-63.51, P=0.02; multivariate, HR=7.44, P=0.01). Overall, the current study revealed the clinical importance of the LN response to NAC for predicting survival outcomes in patients with GC. These findings highlight the potential clinical impact of optimizing treatment strategies to improve the selection and management of patients. (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13535 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245824 ● Search Scopus @ Elsevier (PMID): 36245824 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13535 (DOI: 10.3892/ol.2022.13535, PubMed: 36245824)
16.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Computed tomography texture analysis for the prediction of lateral pelvic lymph node metastasis of rectal cancer., World Journal of Surgical Oncology, Vol.20, No.1, 281, 2022. (Summary) This study aimed to investigate the usefulness of computed tomography (CT) texture analysis in the diagnosis of lateral pelvic lymph node (LPLN) metastasis of rectal cancer. This was a retrospective cohort study of 45 patients with rectal cancer who underwent surgery with LPLN dissection at Tokushima University Hospital from January 2017 to December 2021. The texture analysis of the LPLNs was performed on preoperative CT images, and 18 parameters were calculated. The correlation between each parameter and pathological LPLN metastasis was evaluated. The texture parameters were compared between pathologically metastasis-positive LPLNs and metastasis-negative LPLNs. A total of 40 LPLNs were extracted from 25 patients by preoperative CT scans. No LPLNs could be identified in the remaining 19 patients. Eight of the 25 patients had pathologically positive LPLN metastasis. Extracted LPLNs were analyzed by the texture analysis. Pathologically metastasis-positive LPLNs had significantly lower mean Hounsfield unit, gray-level co-occurrence matrix (GLCM) energy, and GLCM Entropy_log2 values, and a significantly larger volume than pathologically metastasis-negative LPLNs. Multivariate analysis revealed that the independent predictive factors for LPLN metastasis were volume (a conventional parameter) (odds ratio 7.81, 95% confidence interval 1.42-43.1, p value 0.018) and GLCM Entropy_log2 (a texture parameter) (odds ratio 12.7, 95% confidence interval 1.28-126.0, p value 0.030). The combination of both parameters improved the diagnostic specificity while maintaining the sensitivity compared with each parameter alone. Combining the CT texture analysis with conventional diagnostic imaging may increase the accuracy of the diagnosis of LPLN metastasis of rectal cancer. (Keyword) Humans / Lymph Node Excision / Lymph Nodes / Lymphatic Metastasis / Rectal Neoplasms / Retrospective Studies / Tomography, X-Ray Computed (Tokushima University Institutional Repository) ● Metadata: 118078 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-022-02750-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36057660 ● Search Scopus @ Elsevier (PMID): 36057660 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-022-02750-8 (Tokushima University Institutional Repository: 118078, DOI: 10.1186/s12957-022-02750-8, PubMed: 36057660)
17.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Syoko Yamashita : Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study., International Journal of Clinical Oncology, Vol.27, No.9, 1439-1449, 2022. (Summary) This study was performed to assess the impact of osteopenia on chemotherapy-induced neutropenia and the prognosis for patients treated with FOLFOXIRI for colorectal cancer. In total, 77 patients who underwent FOLFOXIRI for un-resectable metastatic and advanced colorectal cancer were retrospectively evaluated. Osteopenia was evaluated by the bone mineral density, which was measured using the average pixel density of the trabecular bone in the 11th thoracic vertebra by computed tomography before the introduction of chemotherapy. The relationship between osteopenia and neutropenia was evaluated. Progression-free survival and overall survival of patients with osteopenia and patients with neutropenia were evaluated. Grade ≥ 3 neutropenia was significantly more common in patients with than without osteopenia (p = 0.002). The multivariate analysis showed that osteopenia was a significant independent predictive factor for grade ≥ 3 neutropenia (p = 0.016). There was no significant difference in progression-free survival or overall survival between patients with and without osteopenia. Patients with grade ≥ 3 neutropenia tended to have a higher progression-free survival rate than others (p = 0.059). The overall survival rate was significantly higher in patients with grade ≥ 3 neutropenia than in others (p = 0.011). Osteopenia might be a predictor of chemotherapy-induced neutropenia, and neutropenia might be a prognostic factor for progression-free survival and overall survival in patients with colorectal cancer treated with FOLFOXIRI. (Keyword) Antineoplastic Agents / Antineoplastic Combined Chemotherapy Protocols / Bevacizumab / Bone Diseases, Metabolic / Camptothecin / Colorectal Neoplasms / Fluorouracil / Humans / Leucovorin / Neutropenia / Organoplatinum Compounds / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-022-02199-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35908137 ● Search Scopus @ Elsevier (PMID): 35908137 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-022-02199-5 (DOI: 10.1007/s10147-022-02199-5, PubMed: 35908137)
18.	Takuya Tokunaga, Maki Sugimoto, Yu Saitou, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, Yosuke Iwakawa, Noriko Yokota and Mitsuo Shimada : Intraoperative holographic image-guided surgery in a transanal approach for rectal cancer., Langenbeck's Archives of Surgery / Deutsche Gesellschaft für Chirurgie, Vol.407, No.6, 2579-2584, 2022. (Summary) Urethral injury is one of the most important complications in transanal total mesorectal excision (TaTME) in male patients with rectal cancer. The purpose of this study was to investigate holographic image-guided surgery in TaTME. Polygon (stereolithography) files were created and exported from SYNAPSE VINCENT, and then uploaded into the Holoeyes MD system (Holoeyes Inc., Tokyo, Japan). After uploading the data, the three-dimensional image was automatically converted into a case-specific hologram. The hologram was then installed into the head mount display, HoloLens (Microsoft Corporation, Redmond, WA). The surgeons and assistants wore the HoloLens when they performed TaTME. In a Wi-Fi-enabled operating room, each surgeon, wearing a HoloLens, shared the same hologram and succeeded in adjusting the hologram by making simple hand gestures from their respective angles. The hologram contributed to better comprehension of the positional relationships between the urethra and the surrounding pelvic organs during surgery. All surgeons were able to properly determine the dissection line. This first experience suggests that intraoperative holograms contributed to reducing the risk of urethral injury and understanding transanal anatomy. Intraoperative holograms have the potential to become a new next-generation surgical support tool for use in spatial awareness and the sharing of information between surgeons. (Keyword) Dissection / Humans / Laparoscopy / Male / Postoperative Complications / Proctectomy / Rectal Neoplasms / Rectum / Surgery, Computer-Assisted / Transanal Endoscopic Surgery (Link to Publication Site) ● Publication site (DOI): 10.1007/s00423-022-02607-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35840706 ● Search Scopus @ Elsevier (PMID): 35840706 ● Search Scopus @ Elsevier (DOI): 10.1007/s00423-022-02607-4 (DOI: 10.1007/s00423-022-02607-4, PubMed: 35840706)
19.	Yuuma Wada, Masaaki Nishi, Kozo Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Preoperative nutrition and exercise intervention in frailty patients with gastric cancer undergoing gastrectomy., International Journal of Clinical Oncology, Vol.27, No.9, 1421-1427, 2022. (Summary) The frailty was associated with the worse surgical outcomes and poor prognosis in several cancers. Therefore, we aimed to identify the usefulness of nutrition and exercise intervention (NEI) in frailty patients with GC. We analyzed 58 frailty patients with GC who underwent radical surgery. Among these, 15 patients were performed NEI by nutritional and rehabilitation support team. We compared the surgical outcomes between NEI and non-NEI groups with frailty patients and evaluated the nutrition and rehabilitation markers in pre- and post-NEI groups. The postoperative complication of NEI groups was 6.7% and less than that of non-NEI groups (p = 0.08). The mean postoperative hospital stay of NEI groups was 13.0 ± 1.0 days for NEI groups and significantly shorter than that of non-NEI groups (p = 0.03). The NLR was 4.3 ± 0.6 for pre-NEI and significantly improved by NEI between pre- and post-NEI (p = 0.03). We identified the clinical importance of NEI for improving the surgical outcomes in frailty patients with GC. Our findings highlight the potential clinical impact of optimizing treatment strategies to select and manage the frailty patients. (Keyword) Exercise Therapy / Frailty / Gastrectomy / Humans / Postoperative Complications / Preoperative Care / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-022-02202-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35771395 ● Search Scopus @ Elsevier (PMID): 35771395 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-022-02202-z (DOI: 10.1007/s10147-022-02202-z, PubMed: 35771395)
20.	Shuhai Chen, Masaaki Nishi, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Akiko Nakamoto, Tohru Sakai and Mitsuo Shimada : Polymethoxylated flavone sudachitin is a safe anticancer adjuvant that targets glycolysis in cancer-associated fibroblasts., Oncology Letters, Vol.24, No.1, 236, 2022. (Summary) Sudachitin is a polymethoxylated flavone found in the peel of , a unique specialty citrus fruit in Tokushima Prefecture, Japan. Previous reports have demonstrated that sudachitin has anti-inflammatory and metabolic regulatory activities. However, to the best of our knowledge, no studies have explored whether sudachitin can act as an antitumor therapeutic agent by regulating metabolic functions in the tumor microenvironment. In the present study, cell proliferation and cytotoxicity assays were used to determine whether sudachitin inhibited the growth of liver cancer and pancreatic carcinoma, cholangiocarcinoma and colorectal cancer cells and to compare its toxicity against normal fibroblasts and induced cancer-associated fibroblasts (CAFs). Using lactate assays and reverse transcription-quantitative PCR, the effects of sudachitin on glycolysis in CAFs were investigated. The effects of CAFs on malignant tumor cells were evaluated using cell proliferation, wound healing and invasion assays. As result, sudachitin inhibited various types of tumor cells with different half-maximal inhibitory concentrations. Treatment with 50 µM sudachitin for 48 h suppressed tumor and CAFs proliferation but was not cytotoxic against normal fibroblasts. This dose also inhibited glycolysis in CAFs and, thus, diminished their pro-tumorigenic activities. Overall, the present study revealed that sudachitin has promise as a safe and widely available natural antitumor adjuvant. (Tokushima University Institutional Repository) ● Metadata: 118072 (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13356 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35720469 ● Search Scopus @ Elsevier (PMID): 35720469 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13356 (Tokushima University Institutional Repository: 118072, DOI: 10.3892/ol.2022.13356, PubMed: 35720469)
21.	Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Chiharu Nakasu and Mitsuo Shimada : Pincer Approach to Gastrosplenic Ligament in Robotic Total Gastrectomy for Gastric Cancer., Journal of Gastrointestinal Surgery, Vol.26, No.7, 1552-1555, 2022. (Keyword) Gastrectomy / Humans / Laparoscopy / Ligaments / Retrospective Studies / Robotic Surgical Procedures / Robotics / Stomach Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1007/s11605-022-05356-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35578006 ● Search Scopus @ Elsevier (PMID): 35578006 ● Search Scopus @ Elsevier (DOI): 10.1007/s11605-022-05356-3 (DOI: 10.1007/s11605-022-05356-3, PubMed: 35578006)
22.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Syoko Yamashita and Yosuke Iwakawa : Vascular variations encountered during laparoscopic surgery for transverse colon, splenic flexure, and descending colon cancer: a retrospective cohort study., BMC Surgery, Vol.22, No.1, 170, 2022. (Summary) Laparoscopic surgery for cancer located in the transverse colon or splenic flexure is difficult because of vascular variability in this region and adjacent vital organs such as the pancreas, spleen, and duodenum. This retrospective cohort study involved 51 patients who underwent laparoscopic surgery for colon cancer at Tokushima University Hospital from July 2015 to December 2020. Variations of the middle colic artery (MCA), left colic artery (LCA), middle colic vein (MCV), and first jejunal vein (FJV) and short-term outcomes of laparoscopic surgery in patients with each vascular variation were evaluated. Variations of the MCA, LCA, MCV, and FJV were classified into four, three, five, and three patterns, respectively. The short-term outcomes of laparoscopic surgery for transverse colon cancer in patients with MCA variations and those with FJV variations were evaluated, and no significant difference was found in the operation time, blood loss, postoperative complication rate, time from surgery to start of dietary intake, or time from surgery to discharge among the different variations. Additionally, no significant differences were found in the short-term outcomes of laparoscopic surgery for descending colon cancer in patients with LCA variations. Preoperative assessment of vascular variations may contribute to the stability of short-term outcomes of laparoscopic surgery for transverse colon, splenic flexure, and descending colon cancer. (Keyword) Colectomy / Colon, Descending / Colon, Transverse / Colonic Neoplasms / Humans / Laparoscopy / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 118005 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-022-01603-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35538458 ● Search Scopus @ Elsevier (PMID): 35538458 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01603-1 (Tokushima University Institutional Repository: 118005, DOI: 10.1186/s12893-022-01603-1, PubMed: 35538458)
23.	Yosuke Iwakawa, Kouzou Yoshikawa, Koichi Okamoto, Tetsuji Takayama, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Mitsuo Shimada : Four cases of gastric adenocarcinoma and proximal polyposis of the stomach treated by robotic total gastrectomy., Surgical Case Reports, Vol.8, No.1, 70, 2022. (Summary) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is a rare disease and characterized by a unique point mutation in the promoter 1B region of the adenomatous polyposis coli (APC) gene. There are two aims in surgery for GAPPS; the first is prophylactic gastrectomy, and the second is excising concurrent cancer. We performed robotic total gastrectomy (RTG) for four cases of GAPPS. Case 1 was a woman in her 40 s whose sister had died from gastric cancer. Mutational analysis revealed mutation of APC exon 1B. We performed prophylactic gastrectomy. Case 2 was a woman in her 30 s who had a mutation of APC exon 1B, and preoperative biopsy revealed suspected adenocarcinoma. Case 3 was a woman in her 40 s who was diagnosed with gastric cancer with multiple polyps in the stomach and a mutation of APC exon 1B. Case 4 was a woman in her 20 s in whom biopsy revealed low-grade dysplasia of a raised lesion. She had a mutation in APC exon 1B. We performed RTG with D1 + lymphadenectomy in all patients, and there were no intraoperative complications. Patients with GAPPS are mainly followed regularly with repeat biopsy, and tumors are detected in an early stage. As the safety of robotic surgery for the early gastric cancer is reported, RTG is an option for these patients. This is the first report of RTG for GAPPS patients. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-022-01425-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35435526 ● Search Scopus @ Elsevier (PMID): 35435526 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-022-01425-6 (DOI: 10.1186/s40792-022-01425-6, PubMed: 35435526)
24.	Toshiaki Yoshimoto, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Shohei Okikawa and Kouzou Yoshikawa : Blue light irradiation inhibits the growth of colon cancer and activation of cancer-associated fibroblasts., Oncology Reports, Vol.47, No.5, 2022. (Summary) Irradiation with a specific wavelength of light using light-emitting diodes (LEDs) has various effects on cells and organisms. Recently, the antitumor effects of visible blue light on tumor cells were reported; however, the mechanism and effects on the tumor microenvironment remain unclear. Human colon cancer cells (HCT-116) were injected into the rectal wall of nude mice. Tumors were irradiated with a 465-nm LED light at 30 mW/cm for 30 min. Tumor volumes and the expression levels of opsin 3 (Opn3), autophagy-related factors, cancer-associated fibroblast (CAF) markers, and programmed cell death 1-ligand (PD-L1) were measured. Additionally, human intestinal fibroblasts were cultured in HCT116-conditioned medium (CM) to prepare CAFs. CAFs were divided into an LED group and a control group, and the effect of the LED light on CAF activation in colon cancer cells was examined. Irradiation with blue LED light suppressed tumor growth; Opn3 expression was localized to the cell membrane in the LED group. Irradiated tumors exhibited increased autophagy-related gene expression. Furthermore, in the LED group, TGF-β and α-SMA expression levels in the fibroblasts were decreased. Regarding CAFs, α-SMA and IL-6 expression levels were decreased in the LED group. HCT-116 cells cultured in CAF-CM with LED irradiation showed no enhanced migration or invasion. In the HCT-116 cells cultured in CM of CAFs irradiated with LED, the relative increase in PD-L1 expression was lower than that noted in the CAF-CM without LED irradiation. Blue LED light may have a direct antitumor effect on colon cancer and also an inhibitory effect on CAFs. (Keyword) Animals / B7-H1 Antigen / Cancer-Associated Fibroblasts / Cell Movement / Cell Proliferation / Colonic Neoplasms / HCT116 Cells / Humans / Light / Mice / Mice, Nude / Rod Opsins / Tumor Microenvironment (Tokushima University Institutional Repository) ● Metadata: 118073 (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2022.8315 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35417035 ● Search Scopus @ Elsevier (PMID): 35417035 ● Search Scopus @ Elsevier (DOI): 10.3892/or.2022.8315 (Tokushima University Institutional Repository: 118073, DOI: 10.3892/or.2022.8315, PubMed: 35417035)
25.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Syoko Yamashita and Yosuke Iwakawa : Risk factors for postoperative ileus after diverting loop ileostomy closure., BMC Surgery, Vol.22, No.1, 131, 2022. (Summary) Postoperative ileus is one of the most common complications after diverting loop ileostomy closure. Some reports have investigated the risk factors for postoperative complications or ileus after ileostomy closure; however, these studies did not evaluate the index surgery sufficiently. In this study, we evaluated the risk factors, including the details of the index surgery, for ileus after diverting ileostomy closure. This was a retrospective study of patients who underwent ileostomy closure following index surgery for rectal cancer. Patients who developed postoperative ileus [POI (+)] and patients who did not [POI (-)] after ileostomy closure were compared. Sixty-eight patients were evaluated and were divided into two groups: POI (+) (n = 11) and POI (-) (n = 57), and the groups were compared. There were no significant differences in the details of the index surgery, operative procedure, transanal total mesorectal excision, lateral lymph node dissection, operating time, or blood loss. The incidence of Clavien-Dindo grade ≥ III complications and adjuvant chemotherapy after index surgery were significantly higher in the POI (+) group. The incidence of Clavien-Dindo grade ≥ III complications and adjuvant chemotherapy after index surgery may increase the risk of postoperative ileus after ileostomy closure. (Keyword) Humans / Ileostomy / Ileus / Postoperative Complications / Rectal Neoplasms / Retrospective Studies / Risk Factors (Tokushima University Institutional Repository) ● Metadata: 118004 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-022-01583-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35392877 ● Search Scopus @ Elsevier (PMID): 35392877 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01583-2 (Tokushima University Institutional Repository: 118004, DOI: 10.1186/s12893-022-01583-2, PubMed: 35392877)
26.	Masaaki Nishi, Mitsuo Shimada, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yuuma Wada : 【外科代謝栄養と東洋医学:漢方による周術期管理へのサポート】大建中湯による周術期管理のサポート, The Japanese Journal of Surgical Metabolism and Nutrition, Vol.56, No.2, 59-61, 2022. (Summary) 近年では漢方の分子生物学的な作用機序の解明が進み，臨床においても質の高いランダム化比較試験により漢方の有用性が明らかになってきた．現在では大建中湯を含む多くの漢方製剤が広く臨床の現場で用いられている．大建中湯は乾姜，人参，山椒の3つの生薬に膠飴を加えた漢方で，外科領域においては癒着性イレウスや麻痺性イレウス，過敏性腸症候群，クローン病などを適応とし，消化管運動促進作用，腸管血流増加作用，抗炎症作用などが報告されている．近年では，食道・胃・大腸・肝臓・膵臓・肝移植外科それぞれの領域でランダム化試験が実施され，大建中湯の周術期管理における有効性が証明されている．また分子生物学的なメカニズムについても解明がすすみ，現在，大建中湯は消化管外科・肝胆膵外科の分野を問わず消化器外科全般における周術期管理のkey drugとして位置付けられている．本稿では消化器外科領域における大建中湯による周術期管理のサポートについて概説する．(著者抄録) (Keyword) 消化管運動消化器外科バクテリアルトランスロケーション周術期管理 *大建中湯(薬理学,治療的利用) 伊東細胞腫瘍微小環境ヒト (Link to Publication Site) ● Publication site (DOI): 10.11638/jssmn.56.2_59 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11638/jssmn.56.2_59 (DOI: 10.11638/jssmn.56.2_59)
27.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Yosuke Iwakawa : The correlation of immunoscore and frailty in colorectal cancer., International Journal of Clinical Oncology, Vol.27, No.3, 528-537, 2022. (Summary) The Immunoscore is a useful prognostic and predictive factor for colorectal cancer. Frailty predicts overall and recurrence-free survival following resection of colorectal cancer, and the immunosuppressive state of frailty might affect tumor progression. This study investigated the relationship between the Immunoscore and frailty in colorectal cancer. This retrospective study included patients who underwent radical surgery for stage II and III colorectal cancer (n = 108). Patients were divided into frail (n = 11) and non-frail (n = 97) groups, and low (IS0-2) (n = 70) and high (IS3-4) Immunoscore groups (n = 38), for comparison. American Society of Anesthesiologists physical status was higher, tumor diameter was larger, number of well-differentiated tumors was higher, albumin was lower, 5-year overall survival (OS) was lower (frail group: 50.0%, non-frail group: 90.5%, p < 0.001) and 5-year disease-free survival (DFS) was lower (frail group: 36.4%, non-frail group: 75.2%, p = 0.024) in the frail than in the non-frail group. Left colon cancer was more, 5-year OS was lower (IS0-2 group: 82.0%, IS3-4 group: 96.7%, p = 0.040) and 5-year DFS was lower (IS0-2 group: 66.3%, IS3-4 group: 83.3%, p = 0.043) in the IS0-2 than in the IS3-4 group. The Immunoscore was lower in the frail than in the non-frail group. Immunoscore and frailty are prognostic and predictive factors in colorectal cancer, and they are correlated with each other. The immunosuppressive state from frailty might affect this correlation. (Keyword) Colonic Neoplasms / Colorectal Neoplasms / Disease-Free Survival / Frailty / Humans / Prognosis / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-021-02096-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34846645 ● Search Scopus @ Elsevier (PMID): 34846645 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-021-02096-3 (DOI: 10.1007/s10147-021-02096-3, PubMed: 34846645)
28.	Yuuma Wada, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hideo Baba, Masaki Mori and Ajay Goel : A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma., British Journal of Cancer, Vol.126, No.8, 1196-1204, 2022. (Summary) The prognosis in patients with intrahepatic cholangiocarcinoma (ICC) is generally poor. To improve treatment selection, we sought to identify microRNA (miRNA) signature associated with survival outcomes in ICC. We first analysed the miRNA expression profiles of primary ICC from two public datasets to identify a miRNA panel to detect patients for short-term survival. We then analysed 309 specimens, including 241 FFPE samples from two clinical cohorts (training: n = 177; validation: n = 64) and matched plasma samples (n = 68), and developed a risk-stratification model incorporating the panel and CA 19-9 levels to predict survival outcomes in ICC. We identified a 7-miRNA panel that robustly classified patients with poor outcomes in the discovery cohorts (AUC = 0.80 and 0.88, respectively). We subsequently trained this miRNA panel in a clinical cohort (AUC = 0.83) and evaluated its performance in an independent validation cohort (AUC = 0.82) and plasma samples from the additional validation cohort (AUC = 0.78). Patients in both clinical cohorts who were classified as high-risk had significantly worse prognosis (p < 0.01). The risk-stratification model demonstrated superior performance compared to models (AUC = 0.85). We established a novel miRNA signature that could robustly predict survival outcomes in resected tissues and liquid biopsies to improve the clinical management of patients with ICC. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Humans / MicroRNAs / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1038/s41416-022-01710-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35079106 ● Search Scopus @ Elsevier (PMID): 35079106 ● Search Scopus @ Elsevier (DOI): 10.1038/s41416-022-01710-z (DOI: 10.1038/s41416-022-01710-z, PubMed: 35079106)
29.	Yuuma Wada, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hideo Baba, Masaki Mori and Ajay Goel : A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases., European Journal of Cancer, Vol.163, 66-76, 2022. (Summary) Cancer recurrence is an important predictor of survival outcomes in patients with colorectal cancer-associated liver metastasis (CRLM), who undergo radical hepatectomy. Therefore, identification of patients with the greatest risk of recurrence is critical for developing a precision oncology strategy that might include frequent surveillance (in low-risk patients) or a more aggressive treatment approach (in high-risk patients). We performed genome-wide expression profiling, to identify and develop a transcriptomic signature for predicting recurrence in patients with CRLM. We analysed a total of 383 patients with CRLM, including 63 patients from a publicly available data set (the NCBI's Gene Expression Omnibus with accession number GSE81423). and 320 patients from whom surgical specimens were collected for independent training (n = 169) and validation (n = 151) of identified biomarkers. Using Cox's proportional hazard regression analysis, we evaluated the clinical significance of the identified gene signature by comparing its performance with several key clinical factors. We identified a six-gene panel that robustly categorised patients with recurrence in the discovery (area under the curve (AUC) = 0.90). We showed that the panel was a significant predictor of recurrence in the clinical training (AUC = 0.83) and validation cohorts (AUC = 0.81). By combining our panel with key clinical factors, we established a risk-stratification model that emerged as an independent predictor of recurrence (AUC = 0.85; univariate: hazard ratio (HR) = 4.34, 95% confidence interval (CI) = 2.71-6.93, P < 0.001; multivariate: HR = 3.40, 95% CI = 1.76-6.56, P < 0.001). The stratification model revealed recurrence prediction in 89% of high-risk group and non-recurrence in 62% of low-risk group. We established a novel transcriptomic signature that robustly predicts recurrence, which has significant implications for the management of patients with CRLM. (Keyword) Biomarkers, Tumor / Colorectal Neoplasms / Gene Expression Regulation, Neoplastic / Hepatectomy / Humans / Liver Neoplasms / Neoplasm Recurrence, Local / Precision Medicine / Prognosis / Transcriptome (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejca.2021.12.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35042069 ● Search Scopus @ Elsevier (PMID): 35042069 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejca.2021.12.013 (DOI: 10.1016/j.ejca.2021.12.013, PubMed: 35042069)
30.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Shoko Yamashita : Propensity Score-Matched Analysis of the Short- and Long-Term Outcomes of Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer., Annals of Surgical Oncology, Vol.29, No.6, 3887-3895, 2022. (Summary) Robotic gastrectomy (RG) has been rapidly adopted for gastric cancer (GC) treatment. However, the benefits of RG over laparoscopic gastrectomy (LG) for GC remain unclear. A total of 451 patients who underwent either RG (n = 83) or LG (n = 368) for GC were enrolled in this study. A 1:1 matched, propensity score-matched analysis was performed using the following factors: age, sex, body mass index, pT, pN, pStage, tumor location, vessel invasion, tumor markers, surgical procedure, reconstruction method, extent of lymphadenectomy, and Endoscopic Surgical Skill Qualification System qualified surgeon as an operator. The surgical outcomes of the two groups were compared. A well-balanced cohort of 158 patients was analyzed (n = 79 in the RG group, n = 79 in the LG group). Regarding the short-term outcomes, the respective blood loss volume, drain amylase content, and number of retrieved lymph nodes in the RG and LG groups were 38.62 ± 73.06 ml and 67.53 ± 108.20 ml (p < 0.05), 450 ± 371 IU/l and 1590 ± 6392 IU/l (p < 0.01), and 35.02 ± 15.51 and 25.28 ± 11.70 (p < 0.01). The morbidity rate was similar between the RG and LG groups (not significant [NS]). Regarding the long-term survival outcomes, there were no intergroup differences in 3-year overall survival (91.72% in the RG group vs. 83.39% in the LG group: NS) and 3-year, disease-free survival (93.31% in the vs. 90.44%: NS). RG was safe and contributed to better short-term outcomes and similar long-term survival outcomes compared with LG. (Keyword) Gastrectomy / Humans / Laparoscopy / Postoperative Complications / Propensity Score / Retrospective Studies / Robotic Surgical Procedures / Stomach Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-021-11203-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35006502 ● Search Scopus @ Elsevier (PMID): 35006502 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-021-11203-7 (DOI: 10.1245/s10434-021-11203-7, PubMed: 35006502)
31.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu and Yuuma Wada : ASO Author Reflections: The Role of Robotic Gastrectomy for Gastric Cancer., Annals of Surgical Oncology, Vol.29, No.6, 3896-3897, 2022. (Keyword) Gastrectomy / Humans / Robotic Surgical Procedures / Robotics / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-021-11226-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34988837 ● Search Scopus @ Elsevier (PMID): 34988837 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-021-11226-0 (DOI: 10.1245/s10434-021-11226-0, PubMed: 34988837)
32.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : Short-term outcomes of laparoscopic / robotic gastrectomy compared with open gastrectomy for advanced gastric cancer following chemotherapy., The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 261-265, 2022. (Summary) Purpose : This study aimed to investigate the short-term outcomes of laparoscopic gastrectomy / robotic gastrectomy after chemotherapy in patients with advanced gastric cancer and compare these outcomes with those of open gastrectomy. Methods : Fifty patients who underwent radical gastrectomy for advanced gastric cancer after chemotherapy between 2007 and 2021 were retrospectively analyzed. The patients were divided into two groups : the laparoscopic gastrectomy / robotic gastrectomy (n = 11) and open gastrectomy (n = 39) groups. The short-term outcomes of these procedures were subsequently examined. Results : The laparoscopic gastrectomy / robotic gastrectomy group had significantly shorter hospital stays and lower intraoperative blood loss than the open gastrectomy group. The overall complication rates were 12.8% (5 of 39 patients) and 0% (0 of 11 patients) in the open gastrectomy and laparoscopic gastrectomy / robotic gastrectomy groups, respectively (P = 0.1). Conclusions : Laparoscopic gastrectomy / robotic gastrectomy may be a surgical option after chemotherapy for patients with advanced gastric cancer. J. Med. Invest. 69 : 261-265, August, 2022. (Keyword) Gastrectomy / Humans / Laparoscopy / Retrospective Studies / Robotic Surgical Procedures / Stomach Neoplasms / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 117728 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.261 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244778 ● Search Scopus @ Elsevier (PMID): 36244778 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.261 (Tokushima University Institutional Repository: 117728, DOI: 10.2152/jmi.69.261, PubMed: 36244778)
33.	Yuuma Wada, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Zhongxu Zhu, Xin Wang, Ane Etxart, Yangsoon Park, Luis Bujanda, In Ja Park and Ajay Goel : Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer., JCO Precision Oncology, Vol.5, 2021. (Summary) Patients with locally advanced rectal cancer (LARC) are recommended to receive preoperative chemoradiotherapy (PCRT) followed by surgery. Response to PCRT varies widely: 60%-70% of patients with LARC do not derive therapeutic benefit from PCRT, whereas 15%-20% of patients achieve pathologic complete response (pCR). We sought to develop a liquid biopsy assay for identifying response to PCRT in patients with LARC. We analyzed two genome-wide microRNA (miRNA) expression profiling data sets from tumor tissue samples for discovery (GSE68204) and validation (GSE29298). We prioritized biomarkers in pretreatment plasma specimens from clinical training (n = 41; 15 responders and 26 nonresponders) and validation (n = 65; 29 responders and 36 nonresponders) cohorts of patients with LARC. We developed an integrated miRNA panel and established a risk assessment model, which was combined with the miRNA panel and carcinoembryonic antigen levels. Our comprehensive discovery effort identified an 8-miRNA panel that robustly predicted response to PCRT, with an excellent accuracy in the discovery (area under the curve [AUC] = 0.95) and validation (AUC = 0.92) cohorts. We successfully established a circulating miRNA panel with remarkable diagnostic accuracy in the clinical training (AUC = 0.82) and validation (AUC = 0.81) cohorts. Moreover, the predictive accuracy of the panel was significantly superior to conventional clinical factors in both cohorts ( < .01) and the risk assessment model was superior (AUC = 0.83). Finally, we applied our model to detect patients with pathologic complete response and showed that it was dramatically superior to currently used pathologic features (AUC = 0.92). Our novel risk assessment signature for predicting response to PCRT has a potential for clinical translation as a liquid biopsy assay in patients with LARC. (Keyword) Chemoradiotherapy / Circulating MicroRNA / Humans / Liquid Biopsy / MicroRNAs / Rectal Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1200/PO.21.00015 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34913022 ● Search Scopus @ Elsevier (PMID): 34913022 ● Search Scopus @ Elsevier (DOI): 10.1200/PO.21.00015 (DOI: 10.1200/PO.21.00015, PubMed: 34913022)
34.	Masaaki Nishi, Mitsuo Shimada, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuuma Wada, Shohei Eto and Toshiaki Yoshimoto : Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer., World Journal of Surgical Oncology, Vol.19, No.1, 201, 2021. (Summary) The lymphocyte to C-reactive protein (CRP) ratio (LCR) is an indicator of systemic inflammation and host-tumor cell interactions. The aim of this study was to investigate the prognostic significance of LCR in lower rectal cancer patients who received preoperative chemo-radiotherapy (CRT). Forty-eight patients with lower rectal cancer who underwent CRT followed by curative surgery were enrolled in this study. Routine blood examinations were performed before and after CRT were used to calculate pre-CRT LCR and post-CRT LCR. The median LCR was used to stratify patients into low and high LCR groups for analysis. The correlation between pre- and post-CRT LCR and clinical outcomes was retrospectively investigated. The pre-CRT LCR was significantly higher than the post-CRT LCR (11,765 and 6780, respectively, P < 0.05). The 5-year overall survival rate was significantly higher for patients with high post-CRT LCR compared with low post-CRT LCR (90.6% and 65.5%, respectively, P < 0.05). In univariate analysis, post-CRT LCR, post-CRT neutrophil to lymphocyte ratio, and fStage were significant prognostic factors for overall survival. In multivariate analysis, post-CRT LCR, but not other clinicopathological factors or prognostic indexes, was a significant prognostic factor for overall survival (P < 0.05). Post-CRT LCR could be a prognostic biomarker for patients with lower rectal cancer. (Keyword) C-Reactive Protein / Chemoradiotherapy / Humans / Lymphocytes / Neoplasm Staging / Prognosis / Rectal Neoplasms / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 117394 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-021-02319-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34229704 ● Search Scopus @ Elsevier (PMID): 34229704 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02319-x (Tokushima University Institutional Repository: 117394, DOI: 10.1186/s12957-021-02319-x, PubMed: 34229704)
35.	Yuuma Wada, Mitsuo Shimada, Tatsuro Murano, Hiroyuki Takamaru, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Francesc Balaguer, Luis Bujanda, Maria Pellise, Ken Kato, Yutaka Saito, Hiroaki Ikematsu and Ajay Goel : A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer., Gastroenterology, Vol.161, No.1, 151-162.e1, 2021. (Summary) We recently reported use of tissue-based transcriptomic biomarkers (microRNA [miRNA] or messenger RNA [mRNA]) for identification of lymph node metastasis (LNM) in patients with invasive submucosal colorectal cancers (T1 CRC). In this study, we translated our tissue-based biomarkers into a blood-based liquid biopsy assay for noninvasive detection of LNM in patients with high-risk T1 CRC. We analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from 2 clinical cohorts-a training cohort (N = 46) and a validation cohort (N = 142)-and matched formalin-fixed paraffin-embedded samples (N = 142). We performed quantitative reverse-transcription polymerase chain reaction, followed by logistic regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model combined with clinical risk factors. We used comprehensive expression profiling of a training cohort of LNM-positive and LMN-negative serum specimens to identify an optimized transcriptomic panel of 4 miRNAs (miR-181b, miR-193b, miR-195, and miR-411) and 5 mRNAs (AMT, forkhead box A1 [FOXA1], polymeric immunoglobulin receptor [PIGR], matrix metalloproteinase 1 [MMP1], and matrix metalloproteinase 9 [MMP9]), which robustly identified patients with LNM (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.72-0.94). We validated panel performance in an independent validation cohort (AUC, 0.82; 95% CI, 0.74-0.88). Our risk-stratification model was more accurate than the panel and an independent predictor for identification of LNM (AUC, 0.90; univariate: odds ratio [OR], 37.17; 95% CI, 4.48-308.35; P < .001; multivariate: OR, 17.28; 95% CI, 1.82-164.07; P = .013). The model limited potential overtreatment to only 18% of all patients, which is dramatically superior to pathologic features that are currently used (92%). A novel risk-stratification model for noninvasive identification of T1 CRC has the potential to avoid unnecessary operations for patients classified as high-risk by conventional risk-classification criteria. (Keyword) Adult / Aged / Aged, 80 and over / Biomarkers, Tumor / Colorectal Neoplasms / Decision Support Techniques / Feasibility Studies / Female / Gene Expression Profiling / Hepatocyte Nuclear Factor 3-alpha / Humans / Liquid Biopsy / Lymph Nodes / Lymphatic Metastasis / Male / Matrix Metalloproteinase 1 / Matrix Metalloproteinase 9 / MicroRNAs / Middle Aged / Neoplasm Staging / Nomograms / Predictive Value of Tests / RNA, Messenger / Receptors, Polymeric Immunoglobulin / Reproducibility of Results / Retrospective Studies / Risk Assessment / Risk Factors / Transcriptome / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1053/j.gastro.2021.03.062 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33819484 ● Search Scopus @ Elsevier (PMID): 33819484 ● Search Scopus @ Elsevier (DOI): 10.1053/j.gastro.2021.03.062 (DOI: 10.1053/j.gastro.2021.03.062, PubMed: 33819484)
36.	Yuuma Wada, Mitsuo Shimada, Kensuke Yamamura, Takeo Toshima, Jasjit K. Banwait, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hideo Baba, Masaki Morishima and Ajay Goel : A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma., Hepatology, Vol.74, No.3, 1371-1383, 2021. (Summary) Tumor recurrence is frequent even in intrahepatic cholangiocarcinoma (ICC), and improved strategies are needed to identify patients at highest risk for such recurrence. We performed genome-wide expression profile analyses to discover and validate a gene signature associated with recurrence in patients with ICC. For biomarker discovery, we analyzed genome-wide transcriptomic profiling in ICC tumors from two public data sets: The Cancer Genome Atlas (n = 27) and GSE107943 (n = 28). We identified an eight-gene panel (BIRC5 [baculoviral IAP repeat containing 5], CDC20 [cell division cycle 20], CDH2 [cadherin 2], CENPW [centromere protein W], JPH1 [junctophilin 1], MAD2L1 [mitotic arrest deficient 2 like 1], NEIL3 [Nei like DNA glycosylase 3], and POC1A [POC1 centriolar protein A]) that robustly identified patients with recurrence in the discovery (AUC = 0.92) and in silico validation cohorts (AUC = 0.91). We next analyzed 241 specimens from patients with ICC (training cohort, n = 64; validation cohort, n = 177), followed by Cox proportional hazard regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model for recurrence in ICC. We subsequently trained this transcriptomic panel in a clinical cohort (AUC = 0.89; 95% confidence interval [CI] = 0.79-0.95), followed by evaluating its performance in an independent validation cohort (AUC = 0.86; 95% CI = 0.80-0.90). By combining our transcriptomic panel with various clinicopathologic features, we established a risk-stratification model that was significantly superior for the identification of recurrence (AUC = 0.89; univariate HR = 6.08, 95% CI = 3.55-10.41, P < 0.01; and multivariate HR = 3.49, 95% CI = 1.81-6.71, P < 0.01). The risk-stratification model identified potential recurrence in 85% of high-risk patients and nonrecurrence in 76% of low-risk patients, which is dramatically superior to currently used pathological features. We report a transcriptomic signature for risk-stratification and recurrence prediction that is superior to currently used clinicopathological features in patients with ICC. (Link to Publication Site) ● Publication site (DOI): 10.1002/hep.31803 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33725402 ● Search Scopus @ Elsevier (PMID): 33725402 ● Search Scopus @ Elsevier (DOI): 10.1002/hep.31803 (DOI: 10.1002/hep.31803, PubMed: 33725402)
37.	Yuuma Wada, Kazunori Tokuda, Yuji Morine, Shohei Okikawa, Shoko Yamashita, Tetsuya Ikemoto, Satoru Imura, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The inhibitory effect of TU-100 on hepatic stellate cell activation in the tumor microenvironment., Oncotarget, Vol.11, No.49, 4593-4604, 2020. (Summary) The tumor microenvironment is involved in acquiring tumor malignancies of colorectal liver metastasis (CRLM). We have reported that TU-100 (Daikenchuto) suppresses hepatic stellate cell (HSC) activation in obstructive jaundice. In this study, we report new findings as the direct and indirect inhibitory effects of TU-100 on cancer cell growth through the suppression of HSC activation. The HSCs (LX2) were cultured in colon cancer cells (HCT116 and HT29)-conditioned medium (CM) with or without TU-100 treatment (90, 270, 900 g/ml). Activated HSCs (aHSCs) were detected by -SMA and IL-6 mRNA expressions and cytokine arrays of HSC's culture supernatants. Cancer cell growth was analyzed for proliferation and migration ability, compared with TU-100 treatment. To investigate the direct anti-tumor effect of TU-100, cancer cells were cultured in the presence of aHSC-CM and TU-100 (90, 270, 900) or aHSC-CM alone, and assessed autophagosomes, conversion to LC3-II protein, and Beclin-1 mRNA expression. Colon cancer-CM significantly increased -SMA and IL-6 mRNA expressions of aHSC. -SMA and IL-6 mRNA expressions of aHSC, and IL-6 secretions from aHSCs were significantly decreased with TU-100 (270, 900) treatment, compared to colon cancer-CM alone. Compared with normal culture medium, aHSC-CM led to a significantly increased cell number and modified HSC-CM (TU-100; 270, 900) significantly suppressed cancer cell growth and migration. TU-100 (900) treatment induced autophagy and significantly promoted the autophagic cell death. TU-100 inhibited colon cancer cell malignant potential by both suppressing HSC activation and inducing directly autophagy of cancer cells. (Tokushima University Institutional Repository) ● Metadata: 116616 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27835 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33346211 ● Search Scopus @ Elsevier (PMID): 33346211 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27835 (Tokushima University Institutional Repository: 116616, DOI: 10.18632/oncotarget.27835, PubMed: 33346211)
38.	Tetsuya Ikemoto, Kazunori Tokuda, Yuuma Wada, Luping Gao, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Adipose Tissue From Type 1 Diabetes Mellitus Patients Can Be Used to Generate Insulin-Producing Cells., Pancreas, Vol.49, No.9, 1225-1231, 2020. (Summary) We aimed to determine whether responsive insulin-producing cells (IPCs) could be generated from adipose-derived stem cells (ADSCs) isolated from patients with type 1 diabetes mellitus (T1DM). We isolated ADSCs from adipose tissue of 4 patients (one patient with T1DM and 3 nondiabetic patients), who underwent surgery and differentiated them into IPCs with using a 2-step xeno-antigen free, 3-dimensional culture method. Characteristics of isolated ADSCs, in vitro cell quality, programmed cell death ligand-1 (PDL-1) expression, and transplantation into streptozotocin induced diabetic nude mice were investigated. Adipose-derived stem cells from T1DM patients and commercially obtained ADSCs showed the same surface markers; CD31CD34CD45CD90CD105CD146. Moreover, the generated IPCs at day 21 demonstrated appropriate autonomous insulin secretion (stimulation index, 3.5; standard deviation, 0.8). Nonfasting blood glucose concentrations of IPC-transplanted mice were normal at 30 days. The normalized rate of IPC-transplanted mice was significantly higher than that of the sham-operated group (P < 0.05). Insulin-producing cells generated from T1DM adipose tissue expressed high levels of PDL-1. Insulin-producing cells obtained from adipose tissue of T1DM patients are capable of secreting insulin long-term and achieve normoglycemia after transplantation. Expression of PDL-1 suggests the potential for immune circumvention. (Link to Publication Site) ● Publication site (DOI): 10.1097/MPA.0000000000001663 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32898009 ● Search Scopus @ Elsevier (PMID): 32898009 ● Search Scopus @ Elsevier (DOI): 10.1097/MPA.0000000000001663 (DOI: 10.1097/MPA.0000000000001663, PubMed: 32898009)
39.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Shin-ichiro Yamada and Mitsuo Shimada : HIF-1 expression in liver metastasis but not primary colorectal cancer is associated with prognosis of patients with colorectal liver metastasis., World Journal of Surgical Oncology, Vol.18, No.1, 241, 2020. (Summary) The role of hypoxia-inducible factor-1 (HIF-1 ) in primary colorectal cancer (CRC) and colorectal liver metastasis (CRLM) has remained unclear. The aim of this study was to investigate HIF-1 expression and its association with prognosis in patients with CRLM with a focus on hepatic stellate cells (HSCs). Colon cancer cells were cultured in HSC-conditioned medium (CM), and HIF-1 expression and cell migration were analyzed. Seventy-five patients with CRLM who underwent an initial curative hepatectomy were enrolled. We examined HIF-1 expressions and patient prognosis between primary CRCs and the matched liver metastatic specimens. Activated HSCs induced HIF-1 mRNA and protein expression in colon cancer cells (p < 0.01) and promoted cell migration (p < 0.01). The positive rates of HIF-1 expression in primary CRCs and liver metastases were 68.0 and 72.0%, respectively. There were no differences in overall (OS) and disease-free survival (DFS) of HIF-1 expression in primary CRC. However, HIF-1 expression in liver metastasis correlated to poor prognosis in both OS and DFS. Furthermore, patients with HIF-1 positive expression in liver metastasis had poor prognosis. HIF-1 expression in liver metastasis determines poor prognosis of CRLM patients. HSCs might play a key role in aggressive phenotypes of tumor cells. (Keyword) Colonic Neoplasms / Colorectal Neoplasms / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / Prognosis (Tokushima University Institutional Repository) ● Metadata: 116676 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-020-02012-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32895059 ● Search Scopus @ Elsevier (PMID): 32895059 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-020-02012-5 (Tokushima University Institutional Repository: 116676, DOI: 10.1186/s12957-020-02012-5, PubMed: 32895059)
40.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Toshiaki Yoshimoto and Mitsuo Shimada : Usefulness of virtual three-dimensional image analysis in inguinal hernia as an educational tool., Surgical Endoscopy, Vol.34, No.2, 1923-1928, 2020. (Summary) The pre-operative three-dimensional (3D) imaging technique has resulted in a better surgical outcome for patients and has been used as an education and diagnostic tool. However, there are no reports concerning the usefulness of the 3D imaging technique in laparoscopic transabdominal pre-peritoneal repair (TAPP) so the aim of this study was to investigate the usefulness of the 3D imaging technique in laparoscopic TAPP as an educational tool for medical students. Six (6) patients who underwent laparoscopic TAPP for inguinal hernia were enrolled in this study. 3D reconstruction was performed from pre-operative computed tomography (CT) and the usefulness of pre-operative 3D simulation compared with intra-operative laparoscopic imaging was validated. Moreover, thirty (30) medical students at the university completed a multiple-choice questionnaire (MCQ) to determine the level of their satisfaction and understanding of anatomy resulting from the study. The local anatomy of the patients was identified as the same during the operation as the pre-operative 3D simulation. The results of the MCQ showed that most of the medical students were extremely (23%) or very (67%) satisfied with the effect of pre-operative 3D simulation on the quality of the surgery. Moreover, most students could understand the surgery anatomy by the 3D simulation extremely well (40%) or very well (47%) and agreed on the usefulness of this procedure for learning anatomy. Pre-operative 3D simulation increases the understanding of detailed anatomy and virtual three-dimensional image analysis in laparoscopic TAPP is useful as an educational tool for medical students. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-019-06964-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31312962 ● Search Scopus @ Elsevier (PMID): 31312962 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-019-06964-y (DOI: 10.1007/s00464-019-06964-y, PubMed: 31312962)
41.	Shogo Oota, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Shoko Iwahashi, Yoshimi Bando and Mitsuo Shimada : Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1 for Intrahepatic Cholangiocarcinoma., Anticancer Research, Vol.39, No.11, 6025-6033, 2019. (Summary) Carbohydrate antigen 19-9 (CA19-9) is a poor prognostic marker in intrahepatic cholangiocarcinoma (IHCC). Previous studies have shown a link between hypoxia and CA19-9 in cancer, and we have previously demonstrated a correlation between HDAC1 and HIF-1 in IHCC. Here, we evaluated the expression and correlation of CA19-9 with HIF-1 and HDAC in IHCC. This study included 62 patients with IHCC who underwent primary hepatectomy at our department. Clinicopathological characteristics were examined. Immunohistochemical expression of HIF-1 and HDAC1 in specimens was quantitatively evaluated. Patients with high preoperative serum CA19-9 levels showed clinicopathological characteristics associated with tumour progression. High CA19-9 levels were associated with worse overall and recurrence-free survival. Univariate and multivariate analysis detected high CA19-9 levels as an independent poor prognostic factor for IHCC. Serum CA19-9 was significantly correlated with both HIF-1 and HDAC1 expression. High serum CA19-9 level is a poor prognostic factor for overall survival in IHCC and correlates with HIF-1 and HDAC1 expression. (Keyword) Aged / Bile Duct Neoplasms / Biomarkers, Tumor / CA-19-9 Antigen / Cholangiocarcinoma / female / Follow-Up Studies / Gene Expression Regulation, Neoplastic / Histone Deacetylase 1 / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / male / Neoplasm Recurrence, Local / Prognosis / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13808 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31704828 ● Search Scopus @ Elsevier (PMID): 31704828 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13808 (DOI: 10.21873/anticanres.13808, PubMed: 31704828)
42.	Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The Differences in the Characteristics of Insulin-producing Cells Using Human Adipose-tissue Derived Mesenchymal Stem Cells from Subcutaneous and Visceral Tissues., Scientific Reports, Vol.9, No.1, 13204, 2019. (Summary) The aim of this study was to investigate the characteristics of insulin producing cells (IPCs) differentiated from adipose-tissue derived stem cells (ADSCs) isolated from human subcutaneous and visceral adipose tissues and identify ADSCs suitable for differentiation into efficient and functional IPCs. Subcutaneous and visceral adipose tissues collected from four (4) patients who underwent digestive surgeries at The Tokushima University (000035546) were included in this study. The insulin secretion of the generated IPCs was investigated using surface markers by: fluorescence activated cell sorting (FACS) analysis; cytokine release; proliferation ability of ADSCs; in vitro (glucose-stimulated insulin secretion: (GSIS) test/in vivo (transplantation into streptozotocin-induced diabetic nude mice). The less fat-related inflammatory cytokines secretions were observed (P < 0.05), and the proliferation ability was higher in the subcutaneous ADSCs (P < 0.05). Insulin expression and GISI were higher in the subcutaneous IPCs (P < 0.01 and P < 0.05, respectively). The hyperglycaemic state of all mice that received IPCs from subcutaneous fat tissue converted into normo-glycaemia in thirty (30) days post-transplantation (4/4,100%). Transplanted IPCs were stained using anti-insulin and anti-human leukocyte antigen antibodies. The IPCs generated from the ADSCs freshly isolated from the human fat tissue had sufficient insulin secreting ability in vitro and in vivo. (Tokushima University Institutional Repository) ● Metadata: 114942 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-49701-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31519950 ● Search Scopus @ Elsevier (PMID): 31519950 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-49701-0 (Tokushima University Institutional Repository: 114942, DOI: 10.1038/s41598-019-49701-0, PubMed: 31519950)
43.	Shoko Iwahashi, Masaaki Nishi, Toshiaki Yoshimoto, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Yuuma Wada, Yoshimi Bando and Mitsuo Shimada : A case of gastric heterotopic pancreas with gastroduodenal invagination., Surgical Case Reports, Vol.5, No.1, 110, 2019. (Summary) Heterotopic pancreas (HP) is a rare disease commonly found incidentally on imaging studies, at endoscopy or at autopsy and can be associated with abdominal pain, vomiting, heart burn, gastric outlet obstruction, and even dysphagia in very rare cases. Heinrich's classified HP into three groups, types1-3, with Heinrich's type 3 HP the rarest and difficult to diagnose properly because it has only pancreatic ducts but has no islet and acini. The aim of this study is to report a case of gastric outlet obstruction caused by type 3 HP with gastroduodenal invagination with reference to the literature and diagnosed finally by immuno-histochemical analysis. The case presented is a 40-year-old male presenting with vomiting and abdominal pain. Computed tomography (CT) revealed a cystic mass in the upper abdomen and he was referred to the Tokushima University. Gastric fiber showed that the pedunculated mass originated from the stomach. An open distal gastrectomy was performed. Pathologically, there was small glands proliferation in the sub-mucosal (SM) layer which was membrane and cytoplasm (MUC)1 positive and muscle proliferation. This finding revealed the tumor as HP. Postoperative course was uneventful and the patient was discharged 12 days after surgery. The patient has remained well 12 months after surgery. HP should be considered in the differential diagnosis of SM tumors with gastroduodenal invagination even if this is a rare symptom. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-019-0669-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31292813 ● Search Scopus @ Elsevier (PMID): 31292813 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-019-0669-7 (DOI: 10.1186/s40792-019-0669-7, PubMed: 31292813)
44.	Yuuma Wada, Atsushi Takata, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : The protective effect of epigallocatechin 3-gallate on mouse pancreatic islets via the Nrf2 pathway., Surgery Today, Vol.49, No.6, 536-545, 2019. (Summary) Epigallocatechin 3-gallate (EGCG), a green tea polyphenol, has been shown to have anti-oxidant and anti-inflammatory effects in vitro and in vivo. The aim of this study was to investigate the effects and mechanism of EGCG on isolated pancreatic islets as pre-conditioning for pancreatic islet transplantation. The pancreatic islets were divided into two groups: an islet culture medium group (control) and an islet culture medium with EGCG (100 M) group. We investigated the islet viability, Nrf2 expression, reactive oxygen species (ROS) production, and heme oxygenase-1 (HO-1) mRNA. Five hundred islet equivalents after 12 h of culture for the EGCG 100 M and control group were transplanted under the kidney capsule of streptozotocin-induced diabetic ICR mice. The cell viability and insulin secretion ability in the EGCG group were preserved, and the nuclear translocation of Nrf2 was increased in the EGCG group (p < 0.01). While the HO-1 mRNA levels were also higher in the EGCG group than in the control group (p < 0.05), the ROS production was lower (p < 0.01). An in vivo functional assessment showed that the blood glucose level had decreased in the EGCG group after transplantation (p < 0.01). EGCG protects the viability and function of islets by suppressing ROS production via the Nrf2 pathway. (Keyword) Animals / Blood Glucose / catechin / Cell Survival / gene expression / Heme Oxygenase-1 / In Vitro Techniques / Insulin Secretion / Islets of Langerhans / Islets of Langerhans Transplantation / male / Mice, Inbred C57BL / Mice, Inbred ICR / NF-E2-Related Factor 2 / RNA, Messenger / reactive oxygen species / Tissue Culture Techniques / Transplantation Conditioning (Tokushima University Institutional Repository) ● Metadata: 114154 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-019-1761-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30730004 ● Search Scopus @ Elsevier (PMID): 30730004 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-019-1761-0 (Tokushima University Institutional Repository: 114154, DOI: 10.1007/s00595-019-1761-0, PubMed: 30730004)

Proceeding of International Conference:

1.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Circulating exosomal microRNA signature to predict peritoneal metastasis in patients with advanced gastric cancer., ASCO-GI, San Francisco, Jan. 2024.
2.	Mitsuo Shimada, Yuuma Wada, Takayuki Noma, Yu Saitou and Yuji Morine : The combination of CD8 and TIM3 expression to predict survival outcomes in hepatocellular carcinoma., ASCO-GI 2024, San Francisco, Jan. 2024.
3.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Immunoscore and Frailty in Colorectal Cancer, IASGO-CME Advanced Post-Graduate Course in Kobe 2023, Kobe, Nov. 2023.
4.	Mitsuo Shimada, Tetsuya Ikemoto, Yuuma Wada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and Shogo Oota : Characteristic difference of adiposederived mesenchymal stem cells from subcutaneous and visceral fat tissue for generating insulin-producing cell, ESOT2019, Copenhagen, Sep. 2019.
5.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto and Mitsuo Shimada : Significance of hypoxia inducible factor-1αexpression in colorectal liver metastasis., APASL STC2018, Yokohama, May 2018.
6.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Shogo Oota, Jun Higashijima and Mitsuo Shimada : Significance of hypoxia inducible factor-1 expression in liver metastasis of colorectal cancer., ASCO-GI, San Francisco, Jan. 2018.

Proceeding of Domestic Conference:

1.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌腹膜播種予測におけるエクソソームmiRNAの有用性, 第96回日本胃癌学会総会, Feb. 2024.
2.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 局所進行胃癌に対するロボット支援手術の工夫と成績, 第96回日本胃癌学会総会, Feb. 2024.
3.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対する経裂孔ロボット支援手術, 第96回日本胃癌学会総会, Feb. 2024.
4.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : The ingenuity of robotic surgery for advanced gastric cancer, 第96回日本胃癌学会総会, Feb. 2024.
5.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : エクソソームmiRNAを用いての胃癌腹膜播種の予測, 第56回制癌剤適応研究会, Feb. 2024.
6.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性, 第36回日本内視鏡外科学会総会, Dec. 2023.
7.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : ロボット支援前立腺全摘後の鼠径ヘルニアに対する腹腔鏡下ヘルニア修復術についての検討, 第36回日本内視鏡外科学会総会, Dec. 2023.
8.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 腹腔鏡下胃癌手術におけるトレーニングプログラムの確立, 第36回日本内視鏡外科学会総会, Dec. 2023.
9.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対する経肛門的側方リンパ節郭清の手術手技と短期成績の検討, 第36回日本内視鏡外科学会総会, Dec. 2023.
10.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 局所進行胃癌に対するロボット支援手術の工夫と成績, 第36回日本内視鏡外科学会総会, Dec. 2023.
11.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 非アルコール性脂肪肝炎に対する減量・代謝改善手術の意義, 第36回日本内視鏡外科学会総会, Dec. 2023.
12.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対するロボット手術(経裂孔アプローチ)の有用性, 第36回日本内視鏡外科学会総会, Dec. 2023.
13.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 他臓器浸潤を伴う直腸癌に対する経肛門アプローチの有用性, 第36回日本内視鏡外科学会総会, Dec. 2023.
14.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第36回日本内視鏡外科学会総会, Dec. 2023.
15.	Toshiaki Yoshimoto, Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 再発直腸癌に対する経肛門アプローチにおけるホログラムの有用性, 第32回日本コンピュータ外科学会大会, Dec. 2023.
16.	Yuuma Wada, Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Hiroki Teraoku, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞癌におけるエクソソームmiRNAを介したLenvatinib耐性機序の検討, 第34回日本消化器癌発生学会総会, Nov. 2023.
17.	Takuya Tokunaga, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 青色LEDはmetabolic couplingを抑制することで抗腫瘍効果をもたらす, 第34回日本消化器癌発生学会総会, Nov. 2023.
18.	Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 胃癌腹膜播種診断マーカーの臨床的有用性, 第34回日本消化器癌発生学会総会, Nov. 2023.
19.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 大腸癌におけるImmunoscoreとフレイルの予後に与える影響, 第34回日本消化器癌発生学会総会, Nov. 2023.
20.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 青色LED光による大腸癌の光受容体をターゲットとした治療法の開発, 第85回日本臨床外科学会総会, Nov. 2023.
21.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 腹腔鏡下胃癌手術のトレーニングプログラム, 第85回日本臨床外科学会総会, Nov. 2023.
22.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対するロボット手術(経裂孔)の有用性, 第85回日本臨床外科学会総会, Nov. 2023.
23.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 右側結腸癌に対するロボット支援下手術の可能性∼腹腔鏡手術との比較から∼, 第85回日本臨床外科学会総会, Nov. 2023.
24.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 経肛門アプローチを併用したロボット支援下直腸切除術の有用性, 第85回日本臨床外科学会総会, Nov. 2023.
25.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 上部胃癌に対するロボット支援手術の工夫と成績, 第85回日本臨床外科学会総会, Nov. 2023.
26.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌手術におけるMRIを用いた骨盤神経描出, 第85回日本臨床外科学会総会, Nov. 2023.
27.	Hideya Kashihara, Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 他臓器浸潤を伴う直腸癌に対する経肛門アプローチの有用性, 第61回日本癌治療学会学術集会, Oct. 2023.
28.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下胃癌手術における術前栄養リハビリ介入の有用性, 第61回日本癌治療学会学術集会, Oct. 2023.
29.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌腹膜播種特異的なエクソソーム中miRNAの同定, 第82回日本癌学会学術総会, Sep. 2023.
30.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 上部胃癌に対するロボット支援胃癌手術の定型化-Left-handed LCS and pincer approach-, 第98回中国四国外科学会総会第28回中国四国内視鏡外科研究会, Sep. 2023.
31.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腸内細菌叢の変化からみた減量・代謝改善手術の効果, 第98回中国四国外科学会総会第28回中国四国内視鏡外科研究会, Sep. 2023.
32.	Kouzou Yoshikawa, Mitsuo Shimada, Yuji Morine, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 大建中湯の消化器疾患における役割, 第98回中国四国外科学会総会第28回中国四国内視鏡外科研究会, Sep. 2023.
33.	Toshiaki Yoshimoto, Masaaki Nishi, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 青色LEDによる大腸癌由来CAF制御および抗腫瘍効果, 第78回日本消化器外科学会総会, Jul. 2023.
34.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : エクソソームmiRNAを用いた胃癌腹膜播種の予測, 第78回日本消化器外科学会総会, Jul. 2023.
35.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌手術におけるMRIを用いた骨盤神経描出, 第78回日本消化器外科学会総会, Jul. 2023.
36.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除術後長期効果に影響を及ぼす因子に関する検討, 第78回日本消化器外科学会総会, Jul. 2023.
37.	Chie Takasu, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 高齢者フレイル胃癌患者における術前栄養・運動介入の意義:短期成績を改善するが長期成績には寄与しない, 第78回日本消化器外科学会総会, Jul. 2023.
38.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘出術における術後パスの有用性―PSMによる解析―, 第78回日本消化器外科学会総会, Jul. 2023.
39.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 進行胃癌に対するロボット支援手術の有用性, 第78回日本消化器外科学会総会, Jul. 2023.
40.	Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 経肛門アプローチを用いた拡大骨盤手術手技, 第78回日本消化器外科学会総会, Jul. 2023.
41.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 大腸癌におけるFrailの意義と免疫栄養指標との関連, 日本外科代謝栄養学会第60回学術集会, Jul. 2023.
42.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌術前における栄養，リハビリ介入の検討, 日本外科代謝栄養学会第60回学術集会, Jul. 2023.
43.	Takayuki Noma, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 切除不能進行胃癌に対してSOX-NIVO後Conversion手術を施行した2症例, 第44回癌免疫外科研究会, Jun. 2023.
44.	Chie Takasu, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 女性消化器外科医の技術向上とキャリア育成を目指した取り組み, 日本消化器病学会四国支部第119回例会, Jun. 2023.
45.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : The Correlation of Immunoscore and Frailty in Colorectal Cancer, 第48回日本外科系連合学会学術集会, Jun. 2023.
46.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除における多職種介入周術期管理の有用性, 第48回日本外科系連合学会学術集会, Jun. 2023.
47.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対するロボット支援下手術(経裂孔)の有用性, 第32回日本癌病態治療研究会, Jun. 2023.
48.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌・食道胃接合部癌に対するロボット支援胃癌手術の手術手技, 第77回手術手技研究会, May 2023.
49.	仲須千春, Masaaki Nishi, Yuji Morine, Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Mitsuo Shimada : 青色LEDを用いたCAFの糖代謝に着目した腫瘍免疫制御のメカニズムの解明, 第123回日本外科学会定期学術集会, Apr. 2023.
50.	Chie Takasu, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 高齢者フレイル胃癌患者における術前栄養・運動リハビリの意義: 短期成績を改善するが長期成績には寄与しない, 第123回日本外科学会定期学術集会, Apr. 2023.
51.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌フレイル患者における術前栄養リハビリ介入の有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
52.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腸脳相関からみたMetabolic surgeryの術後早期血糖抑制効果, 第123回日本外科学会定期学術集会, Apr. 2023.
53.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : Utility of robotic surgery for Siewert type II/III adenocarcinoma of esophagogastric junction: transhiatal robotic versus laparoscopic approach, 第123回日本外科学会定期学術集会, Apr. 2023.
54.	Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 髙橋叡 and Mitsuo Shimada : 下部直腸癌に対する経肛門アプローチにおける術中ホログラム手術支援の有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
55.	Toshiaki Yoshimoto, Shohei Okikawa, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 青色LED光の腫瘍微小環境に対する効果, 第123回日本外科学会定期学術集会, Apr. 2023.
56.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するMRIを用いた骨盤神経描出, 第123回日本外科学会定期学術集会, Apr. 2023.
57.	Takuya Tokunaga, Yu Saitou, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 山下祥子, 岩川陽介 and Mitsuo Shimada : 経肛門アプローチを用いた腹腔鏡下側方郭清の手術手技と短期成績 ∼Hologramによるシミュレーションの有用性∼, 第122回日本外科学会定期学術集会, Apr. 2023.
58.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Yuuma Wada, Shin-ichiro Yamada and Yuji Morine : 再生医療を用いたβ細胞補填治療法に関する膵島移植とのクロストーク, 第50回日本膵・膵島移植学会学術集会, Mar. 2023.
59.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Mitsuo Shimada : 胃癌手術における術前栄養リハビリ介入の有用性, 第95回日本胃癌学会総会, Feb. 2023.
60.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌・食道胃接合部癌に対するロボット手術の有用性, 第95回日本胃癌学会総会, Feb. 2023.
61.	Chie Takasu, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 高齢者フレイル胃癌患者における術前栄養・運動介入の意義:短期成績を改善するが長期成績には寄与しない, 第95回日本胃癌学会総会, Feb. 2023.
62.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : MISによる胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第95回日本胃癌学会総会, Feb. 2023.
63.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するホログラムを駆使した新たな経肛門手術, 第266回徳島医学会学術集会, Feb. 2023.
64.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : ロボット支援前立腺全摘後に発症した鼠径ヘルニアに対する腹腔鏡手術症例の検討, 第35回日本内視鏡外科学会総会, Dec. 2022.
65.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第35回日本内視鏡外科学会総会, Dec. 2022.
66.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 経肛門側方リンパ節郭清の手技と短期成績 ∼ホログラムシミュレーションの有用性∼, 第35回日本内視鏡外科学会総会, Dec. 2022.
67.	Chie Takasu, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 腹腔鏡下胃切除における6番リンパ節郭清困難性の術前予測, 第35回日本内視鏡外科学会総会, Dec. 2022.
68.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 食道胃接合部癌に対するロボット支援下手術(経裂孔)の工夫, 第35回日本内視鏡外科学会総会, Dec. 2022.
69.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 低侵襲胃全摘術後再建における肝臓脱転による視野確保とOrVil法の有用性, 第35回日本内視鏡外科学会総会, Dec. 2022.
70.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 髙橋叡 and Mitsuo Shimada : DST吻合における吻合部血流不全のリスク因子および追加切除例の検討, 第84回日本臨床外科学会総会, Nov. 2022.
71.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 局所進行直腸癌に対する術前化学放射線療法におけるADC値の有用性, 第84回日本臨床外科学会総会, Nov. 2022.
72.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第84回日本臨床外科学会総会, Nov. 2022.
73.	Toshihiro Nakao, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下結腸癌手術における体腔内吻合の短期成績, 第84回日本臨床外科学会総会, Nov. 2022.
74.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘出術における術後パスの有用性―PSMによる解析―, 第84回日本臨床外科学会総会, Nov. 2022.
75.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Yuuma Wada, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌に対するロボット支援胃癌手術の定型化- Left-handed LCS and pincer app roach –, 第84回日本臨床外科学会総会, Nov. 2022.
76.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 髙橋叡 : 他臓器浸潤を伴う直腸癌に対する経肛門アプローチの有用性, 第84回日本臨床外科学会総会, Nov. 2022.
77.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第118回日本消化器病学会四国支部例会, Nov. 2022.
78.	Kouzou Yoshikawa, Mitsuo Shimada, Masaaki Nishi, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下胃癌手術における術前栄養リハビリ介入の有用性, 第52回胃外科・術後障害研究会, Nov. 2022.
79.	Masaaki Nishi, 陳術海, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : CAFの糖代謝を標的とした治療法の開発 -フラボノイド(EGCGとSudachitin)の可能性-, 第33回日本消化器癌発生学会総会, Nov. 2022.
80.	Takuya Tokunaga, Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 髙橋叡 and Mitsuo Shimada : 腫瘍関連マクロファージおよび大腸癌に対する青色LEDの効果, 第33回日本消化器癌発生学会総会, Nov. 2022.
81.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 大腸癌におけるImmunoscoreとFrailの相関についての検討, 第33回日本消化器癌発生学会総会, Nov. 2022.
82.	Masaaki Nishi, Chie Takasu, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Yuuma Wada, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 漢方とBacterial translocation-大建中湯の消化管疾患に対する多面的効果の検討-, 第35回日本外科感染症学会総会学術集会, Nov. 2022.
83.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 髙橋叡 and Mitsuo Shimada : 大腸癌手術における予後因子としてのFrailの意義, 第60回日本癌治療学会学術集会, Oct. 2022.
84.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性, 第60回日本癌治療学会学術集会, Oct. 2022.
85.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 上部胃癌に対するロボット手術の工夫 Pincer approach to gastrosplenic ligament, 第60回日本癌治療学会学術集会, Oct. 2022.
86.	Takuya Tokunaga, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 髙橋叡 and Mitsuo Shimada : ハイブリッド側方リンパ節郭清手技と短期成績∼ホログラムシミュレーションの有用性∼, 第60回日本癌治療学会学術集会, Oct. 2022.
87.	Yuuma Wada, Mitsuo Shimada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 局所進行直腸癌における術前化学放射線療法においてADC値の有用性, 第60回日本癌治療学会学術集会, Oct. 2022.
88.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 髙橋叡 : 大腸癌におけるImmunosoreとFrailの相関, 第60回日本癌治療学会学術集会, Oct. 2022.
89.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘出術における術後パスの有用性―PSMによる解析―, 第60回日本癌治療学会学術集会, Oct. 2022.
90.	Hideya Kashihara, Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第77回日本大腸肛門病学会学術集会, Oct. 2022.
91.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 髙橋叡 : 他臓器浸潤直腸癌に対するTpAPR手術手技, 第77回日本大腸肛門病学会学術集会, Oct. 2022.
92.	Yuuma Wada, Masaaki Nishi, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 癌関連線維芽細胞における糖代謝に着目した治療法の可能性, 第81回日本癌学会学術総会, Sep. 2022.
93.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
94.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Yuuma Wada, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌におけるロボット支援胃癌手術の工夫, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
95.	Chie Takasu, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, 髙橋叡 and Mitsuo Shimada : 腹腔鏡下胃切除における幽門下リンパ郭清困難性の術前評価, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
96.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下結腸癌手術における体腔内吻合の短期成績, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
97.	Masaaki Nishi, Shuhai Chen, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : CAFの糖代謝を標的とした治療法の開発-フラボノイド(EGCGとSudachitin)の可能性-, 第265回徳島医学会学術集会, Jul. 2022.
98.	岩川陽介, Masaaki Nishi, Yuuma Wada, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 胃GISTに対するLECSの検討 -腫瘍径5㎝以上に対するLECS-, 第77回日本消化器外科学会総会, Jul. 2022.
99.	Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : Hologramによるシミュレーションを用いた経肛門的側方リンパ節郭清, 第77回日本消化器外科学会総会, Jul. 2022.
100.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 沖川昌平 and Mitsuo Shimada : 大腸癌腫瘍関連マクロファージに対する青色LEDの効果, 第77回日本消化器外科学会総会, Jul. 2022.
101.	Yuuma Wada, Mitsuo Shimada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and 岩川陽介 : 腹腔鏡下胃癌手術における術前栄養リハビリ介入の有用性, 第77回日本消化器外科学会総会, Jul. 2022.
102.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 山下祥子 : 腹腔鏡下スリーブ状胃切除術後長期効果に影響を及ぼす因子に関する検討, 第77回日本消化器外科学会総会, Jul. 2022.
103.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Yuuma Wada and 山下祥子 : 上部胃癌に対するロボット支援胃癌手術の工夫, 第77回日本消化器外科学会総会, Jul. 2022.
104.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 山下祥子 : 胃癌播種診断におけるCTスコアリングシステムを用いた診断率改善の試み, 第77回日本消化器外科学会総会, Jul. 2022.
105.	Takuya Tokunaga, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性, 第31回日本癌病態治療研究会, Jun. 2022.
106.	Yuuma Wada, Kouzou Yoshikawa, Masaaki Nishi, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 進行胃癌に対するロボット支援下胃切除術の有用性, 第117回例会日本消化器病学会四国支部, Jun. 2022.
107.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 山下祥子 : 進行胃癌に対するロボット支援胃切除術の有用性とピットフォール, 第47回日本外科系連合学会学術集会, Jun. 2022.
108.	Toshiaki Yoshimoto, Takuya Tokunaga, Yu Saitou, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, 山下祥子, 岩川陽介 and Mitsuo Shimada : Intraoperative holographic image-guided lateral pelvic lymph node dissection in a transanal approach for rectal cancer, CARS 2022, Jun. 2022.
109.	Takuya Tokunaga, 杉本真樹, Yu Saitou, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 経肛門アプローチ併用ハイブリッド側方リンパ節郭清に対するホログラムの有用性, 第31回日本コンピュータ外科学会大会, Jun. 2022.
110.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : Apparent diffusion coefficient measurements predict survival outcomes after neoadjuvant chemoradiotherapy in locally advanced rectal cancer, 第67回国際外科学会日本部会総会, Jun. 2022.
111.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : ロボット胃癌手術における工夫 -Left handed LCS techniqueとPincer approach for gastro-splenic ligament-, 第76回手術手技研究会, May 2022.
112.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 術前抗がん剤治療を行った進行胃癌に対する低侵襲手術の有用性, 第122回日本外科学会定期学術集会, Apr. 2022.
113.	Takuya Tokunaga, Yu Saitou, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, 岩川陽介 and Mitsuo Shimada : 経肛門アプローチを用いた腹腔鏡下側方郭清の手術手技と短期成績∼Hologramによるシミュレーションの有用性∼, 第122回日本外科学会定期学術集会, Apr. 2022.
114.	Yoshihito Matsuzaki, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : ALS患者の胃癌2切除例, 第122回日本外科学会定期学術集会, Apr. 2022.
115.	Yuuma Wada, Masaaki Nishi, 陳術海, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, 山下祥子, 岩川陽介 and Mitsuo Shimada : 癌関連線維芽細胞の糖代謝を標的とした治療法の開発, 第122回日本外科学会定期学術集会, Apr. 2022.
116.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 山下祥子 and 岩川陽介 : 大腸癌におけるImmunoscoreとフレイルの検討, 第122回日本外科学会定期学術集会, Apr. 2022.
117.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性 - TaTME併用腹腔鏡下直腸切除術との比較から –, 第122回日本外科学会定期学術集会, Apr. 2022.
118.	武原悠花子, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除における多職種介入術前減量プログラムの有用, 第122回日本外科学会定期学術集会, Apr. 2022.
119.	山下祥子, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 岩川陽介 : 直腸癌の放射線化学療法における肥満細胞の役割, 第122回日本外科学会定期学術集会, Apr. 2022.
120.	沖川昌平, Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 山下祥子 and Yuji Morine : Duodenal-jejunal bypassの術後早期血糖抑制効果に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
121.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 沖川昌平, 山下祥子, 岩川陽介 and Mitsuo Shimada : 青色LEDの腫瘍関連マクロファージ(TAM)および大腸癌細胞に対する効果, 第122回日本外科学会定期学術集会, Apr. 2022.
122.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and 山下祥子 : ロボット支援胃癌手術の短期・長期成績-ロボットvs腹腔鏡:プロペンシティスコアマッチ解析-, 第122回日本外科学会定期学術集会, Apr. 2022.
123.	Chie Takasu, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 腹腔鏡下胃切除における幽門下リンパ郭清困難性の術前評価, 第94回日本胃癌学会総会, Mar. 2022.
124.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 高齢者におけるFrailtyの臨床的意義, 第94回日本胃癌学会総会, Mar. 2022.
125.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Shoko Yamashita : Propensity score-matched analysis of the short-and long-term outcomes of RG vs. LG, 第94回日本胃癌学会総会, Mar. 2022.
126.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : The usefulness of the minimal invasive surgery for advanced gastric cancer with preoperative chemotherapy, 第94回日本胃癌学会総会, Mar. 2022.
127.	Chie Takasu, Yuji Morine, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 腸管Microbiome解析からみた大建中湯の消化管疾患に対する多面的効果の検討, 第18回日本消化管学会総会学術集会(GI Week 2022), Feb. 2022.
128.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : ロボット支援下前立腺全摘術後に発症した鼠径ヘルニアの検討, 第34回日本内視鏡外科学会総会, Dec. 2021.
129.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 腹腔鏡・ロボット支援下胃癌手術のトレーニングプログラムの構築, 第34回日本内視鏡外科学会総会, Dec. 2021.
130.	Chie Takasu, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Mitsuo Shimada : 腹腔鏡下胃切除における幽門下リンパ郭清困難性の術前評価, 第34回日本内視鏡外科学会総会, Dec. 2021.
131.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : NASHに対する新たな治療アプローチとしての腹腔鏡下スリーブ状胃切除術, 第34回日本内視鏡外科学会総会, Dec. 2021.
132.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : ロボット支援胃癌手術の有用性, 第34回日本内視鏡外科学会総会, Dec. 2021.
133.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 横行結腸・脾弯曲部・下行結腸癌における血管走行と腹腔鏡下手術手技に関する検討, 第34回日本内視鏡外科学会総会, Dec. 2021.
134.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 他臓器合併切除を要する直腸癌に対するTrasaperineal abdominoperineal resection, 第34回日本内視鏡外科学会総会, Dec. 2021.
135.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除における多職種介入周術期管理の有用性(WS5-2), 第34回日本内視鏡外科学会総会, Dec. 2021.
136.	Kouzou Yoshikawa, Mitsuo Shimada, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : ロボット支援胃癌手術におけるLeft hand LCS techniqueを用いた定型化への取り組み(WS6-7), 第34回日本内視鏡外科学会総会, Dec. 2021.
137.	Toshiaki Yoshimoto, Shohei Okikawa, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : 青色LEDの癌関連線維芽細胞および大腸癌に対する効果, 第32回日本消化器癌発生学会総会, Nov. 2021.
138.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Shoko Yamashita, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and IWAKAWA Yosuke : 直腸癌の放射線化学療法における肥満細胞の役割, 第32回日本消化器癌発生学会総会, Nov. 2021.
139.	Masaaki Nishi, Mitsuo Shimada, 陳述海, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : EGCGがCAFの糖代謝を標的とし，腫瘍悪性度を抑制する, 第32回日本消化器癌発生学会総会, Nov. 2021.
140.	Takuya Tokunaga, 杉本真樹, Yu Saitou, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : 直腸癌に対する経肛門的アプローチにおけるホログラムと尿道造影を併用した術中ナビゲーション, 第30回日本コンピュータ外科学会大会, Nov. 2021.
141.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : ロボット支援胃切除の有用性-Robotic Versus Laparoscopic Gastrectomy: Propensi ty-Matched Analysis.-, 第116回日本消化器病学会四国支部例会, Nov. 2021.
142.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : taTMEの手術手技と治療成績, 第116回日本消化器病学会四国支部例会, Nov. 2021.
143.	IWAKAWA Yosuke, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 胃原発の未分化型多形肉腫の1例, 第83回日本臨床外科学会総会, Nov. 2021.
144.	Shoko Yamashita, Masaaki Nishi, Toshiaki Yoshimoto, Yuuma Wada, Hideya Kashihara, Chie Takasu, Toshihiro Nakao, Takuya Tokunaga, Kouzou Yoshikawa, Koichi Tsuneyama and Mitsuo Shimada : Osteoclast-like giant cellを伴うhamartomatous inverted polypから発生したリンパ球浸潤胃癌の一例, 第83回日本臨床外科学会総会, Nov. 2021.
145.	Shohei Okikawa, Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, IWAKAWA Yosuke and Yuji Morine : Duodenal-jejunal bypassの術後早期血糖抑制効果に関する検討, 第83回日本臨床外科学会総会, Nov. 2021.
146.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : 大腸癌予後因子としてのFrailの意義, 第83回日本臨床外科学会総会, Nov. 2021.
147.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : ロボット支援胃癌手術の標準化, 第83回日本臨床外科学会総会, Nov. 2021.
148.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 直腸切断術に対するTransperineal approachの有用性, 第83回日本臨床外科学会総会, Nov. 2021.
149.	Yuuma Wada, Mitsuo Shimada, Hideya Kashihara, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 腹腔鏡下胃癌手術における術前減量プログラムの有用性, 第83回日本臨床外科学会総会, Nov. 2021.
150.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 腹腔鏡下胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第83回日本臨床外科学会総会, Nov. 2021.
151.	Chie Takasu, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and NAKASU Chiharu : 地方だからこそ発信できるインクルージョンを目指した働き方改革, 第83回日本臨床外科学会総会, Nov. 2021.
152.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shohei Eto and Toshiaki Yoshimoto : ロボット時代の正確な腹膜播種診断に向けての胃癌Staging laparoscopyの有用性, JDDW 2021, Nov. 2021.
153.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Shoko Yamashita : 外科手術におけるFrailtyの重要性, 第51回胃外科・術後障害研究会, Nov. 2021.
154.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, IWAKAWA Yosuke and Mitsuo Shimada : DST吻合における吻合部血流不全のリスク因子:追加切除例の検討, 第59回日本癌治療学会学術集会, Oct. 2021.
155.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 高齢者胃癌患者における外科手術の意義-Frailtyの重要性-, 第59回日本癌治療学会学術集会, Oct. 2021.
156.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 当科におけるTaTME手術手技と治療成績, 第59回日本癌治療学会学術集会, Oct. 2021.
157.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下胃・大腸癌手術における多職種介入術前減量プログラムの有用性, 第59回日本癌治療学会学術集会, Oct. 2021.
158.	Kouzou Yoshikawa, Mitsuo Shimada, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 進行胃癌に対するロボット手術の有用性, 第59回日本癌治療学会学術集会, Oct. 2021.
159.	Yuuma Wada, Mitsuo Shimada, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto, Shoko Yamashita, IWAKAWA Yosuke and Yasuhiro Hamada : 肥満外科手術における術前NLRの有用性, 第27回外科侵襲とサイトカイン研究会, Oct. 2021.
160.	Masaaki Nishi, Mitsuo Shimada, 陳述海, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 癌関連線維芽細胞の糖代謝を標的とした治療法の開発, 第263回徳島医学会学術集会(令和3年度夏期), Aug. 2021.
161.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Shohei Eto : 高齢者胃癌に対するFrailityの意義, 第76回日本消化器外科学会総会, Jul. 2021.
162.	Yuuma Wada, Yuji Morine, Yu Saitou, Satoru Imura, Tetsuya Ikemoto, Masaaki Nishi, Shin-ichiro Yamada, Kazunori Tokuda, Hiroki Teraoku and Mitsuo Shimada : 癌微小環境における大建中湯の癌細胞増殖抑制効果, 第76回日本消化器外科学会総会, Jul. 2021.
163.	Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shohei Okikawa, Shoko Yamashita, IWAKAWA Yosuke and NAKASU Chiharu : 青色LEDの癌関連線維芽細胞および大腸癌細胞に対する効果, 第115回日本消化器病学会四国支部例会, Jun. 2021.
164.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Shohei Eto, Toshiaki Yoshimoto and Yuuma Wada : Robotic Versus Laparoscopic Gastrectomy: Propensity-Matched Analysis, 第93回日本胃癌学会総会, Mar. 2021.
165.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Left handed approach によるロボット支援下胃癌手術, 第74回日本消化器外科学会総会, Jul. 2019.
166.	Masato Yoshikawa, Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Shoko Iwahashi and Mitsuo Shimada : 脂肪由来幹細胞からのインスリン産生細胞分化誘導に関する研究, 第26回外科侵襲とサイトカイン研究会, Jul. 2019.
167.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
168.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto, 西山光恵 and 五十嵐康 : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第105回日本消化器病学会総会, May 2019.
169.	Tomohiko Miyatani, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shogo Oota and Shoko Iwahashi : 直腸癌手術におけるICG蛍光法による血流評価の有用性と定量化, 第119回日本外科学会定期学術集会, Apr. 2019.
170.	Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 大腸癌肝転移における免疫逃避機構は原発巣と異なる可能性がある, 第119回日本外科学会定期学術集会, Apr. 2019.
171.	Shogo Oota, Mitsuo Shimada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto and Shoko Iwahashi : Insulin-producing cell(IPC)分化成熟と亜鉛イオン濃度相関に関する研究, 第119回日本外科学会定期学術集会, Apr. 2019.
172.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Yuuma Wada, Shogo Oota, Shoko Iwahashi and Mitsuo Shimada : 青色LED光のOpn3を介した大腸癌抑制効果 (第2報), 第119回日本外科学会定期学術集会, Apr. 2019.
173.	Yuuma Wada, Yuji Morine, Yu Saitou, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 癌微小環境における大建中湯の肝星細胞活性化制御・癌細胞オートファジーを介した癌細胞増殖抑制効果, 第119回日本外科学会定期学術集会, Apr. 2019.
174.	Shuichi Iwahashi, Tetsuya Ikemoto, Yuuma Wada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 臨床応用に向けたインスリン産生細胞分化誘導に関する研究, 第119回日本外科学会定期学術集会, Apr. 2019.
175.	Shogo Oota, Mitsuo Shimada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto and Shoko Iwahashi : Insulin-producing cell(IPC)分化成熟と亜鉛イオン濃度相関に関する研究, 第18回日本再生医療学会総会, Mar. 2019.
176.	Yuuma Wada, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Shogo Oota, Shoko Iwahashi and Mitsuo Shimada : 脂肪由来幹細胞からのインスリン産生細胞分化誘導に関する研究, 第18回日本再生医療学会総会, Mar. 2019.
177.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Toshiaki Yoshimoto : 肝胆膵領域癌におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第52回制癌剤適応研究会, Mar. 2019.
178.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Hideya Kashihara, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Toshiaki Yoshimoto and Yuuma Wada : 腹腔鏡下胃癌手術のトレーニングプログラムの構築, 第91回日本胃癌学会総会, Feb. 2019.
179.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 安全なロボット支援下胃癌手術の再導入, 第2回徳島外科医会, Feb. 2019.
180.	Yuuma Wada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, 馮睿 and Mitsuo Shimada : 腫瘍関連マクロファージに着目した肝癌細胞悪性度上昇の検討, 第19回日本肝がん分子標的治療研究会, Jan. 2019.
181.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Yuuma Wada : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第19回日本肝がん分子標的治療研究会, Jan. 2019.
182.	Yuuma Wada, Tetsuya Ikemoto, Shuichi Iwahashi, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masaaki Nishi, Satoru Imura and Mitsuo Shimada : 膵島保護におけるNrf2を介した Epigallocatechin-3-gallate (EGCG)の効果, 第48回創傷治癒学会, Nov. 2018.
183.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto and Shogo Oota : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第56回日本癌治療学会学術集会, Oct. 2018.
184.	Masaaki Nishi, Mitsuo Shimada, Chie Takasu, Hideya Kashihara, Kouzou Yoshikawa, Jun Higashijima, Daichi Ishikawa, Takuya Tokunaga, Yuuma Wada and Tomohiko Miyatani : 胃癌におけるCMTM6発現の意義, 第56回日本癌治療学会学術集会, Oct. 2018.
185.	Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Satoru Imura and Mitsuo Shimada : Nrf2経路によるEGCGの膵島保護効果, 第54回日本移植学会総会, Oct. 2018.
186.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : 臨床応用を目指した間葉系幹細胞から創生されるインスリン産生細胞による糖尿病の治療法確立に関する研究, 第54回日本移植学会総会, Oct. 2018.
187.	Tetsuya Ikemoto, Mitsuo Shimada, Shogo Oota, Yuuma Wada, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : 膵癌患者における末梢血Tr1細胞が反映するPDL-1発現の意義に関する検討, 第77回日本癌学会学術集会, Sep. 2018.
188.	Shin-ichiro Yamada, Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : 造影効果から見た肝内胆管癌の腫瘍悪性度に関する検討, 第54回日本胆道学会学術集会, Sep. 2018.
189.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Toshiaki Yoshimoto, Yuuma Wada and Shogo Oota : 長期予後に着目した膵全摘症例の検討-近年の化学療法の発展に伴う治療選択肢として-, 第27回消化器疾患病態治療研究会, Sep. 2018.
190.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Hiroki Teraoku and Shogo Oota : NCDデータからみた地方における消化器外科手術の特色と安全性評価に関する検討, 第73回日本消化器外科学会総会, Jul. 2018.
191.	Masaaki Nishi, Mitsuo Shimada, Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Daichi Ishikawa and Yuuma Wada : CMTM6による胃癌再発機構の解明, 第73回日本消化器外科学会総会, Jul. 2018.
192.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuuma Wada and Shogo Oota : TaTMEにおける尿道損傷回避のための工夫, 第73回日本消化器外科学会総会, Jul. 2018.
193.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : CT動脈相の造影効果から見た肝内胆管癌の腫瘍悪性度に関する検討, 第73回日本消化器外科学会総会, Jul. 2018.
194.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : 集学的治療としての膵全摘症例の検討, 第109回日本消化器病学会四国支部例会, Jun. 2018.
195.	Hiroki Teraoku, Tetsuya Ikemoto, Shogo Oota, Yuuma Wada, Yu Saitou, Shuichi Iwahashi, Satoru Imura, Yuji Morine and Mitsuo Shimada : Preoperative care and surgical management for elderly and/or high-risk patients, 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
196.	Yuuma Wada, Yuji Morine, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, shogo ohta and Mitsuo Shimada : Significance of hypoxia inducible factor-1 expression in liver metastasis of colorectal cancer., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
197.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Daichi Ishikawa and Yuuma Wada : 肥満手術のインスリン抵抗性・NASH改善効果におけるマイクロバイオームの重要性, 第104回日本消化器病学会総会, Apr. 2018.
198.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Shogo Oota and Mitsuo Shimada : 大腸癌肝転移におけるHypoxia Inducible Factor-1発現の意義 -肝転移巣・原発巣における腫瘍悪性度評価-, 第118回日本外科学会定期学術集会, Apr. 2018.
199.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : 肝内胆管癌の造影効果による腫瘍悪性度評価の検討, 第118回日本外科学会定期学術集会, Apr. 2018.
200.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Yuuma Wada and Hiroki Teraoku : Epigallocatechin-3-gallateはNrf2を介して膵島保護作用を有する, 第118回日本外科学会定期学術集会, Apr. 2018.
201.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Hiroki Teraoku and Shogo Oota : 臨床応用を目指した間葉系幹細胞から創生されるインスリン産生細胞による糖尿病の治療法確立に関する研, 第118回日本外科学会定期学術集会, Apr. 2018.
202.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Yuuma Wada : 腫瘍免疫からみた大腸癌再発機構の解明, 第118回日本外科学会定期学術集会, Apr. 2018.
203.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuuma Wada and Shogo Oota : 腹腔鏡下前方切除術におけるICG蛍光法・サーモグラフィーによる血流評価の有用性, 第118回日本外科学会定期学術集会, Apr. 2018.
204.	Hiroki Teraoku, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : Sorafenib投与症例におけるHCC長期生存例の検討, 第51回制癌剤適応研究会, Mar. 2018.
205.	Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Shogo Oota, Satoru Imura and Mitsuo Shimada : Nef2-Keap1経路の膵島保護作用におけるEpigallocatechin-3-gallate(EGCG)の役割, 第47回日本創傷治癒学会, Nov. 2017.
206.	Shogo Oota, Yuuma Wada, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 初回切除後再発膵癌に対する再切除の有用性, 第79回日本臨床外科学会総会, Nov. 2017.
207.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : One stop shopを目指したEOB-MRIによる部分切除術肝機能評価, 第26回日本コンピュータ外科学会大会, Oct. 2017.
208.	Yuuma Wada, Yuji Morine, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Shuichi Iwahashi, Hideya Kashihara, Chie Takasu, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 青色LED光は光受容体(opsin3)を介し癌細胞増殖を抑制する, 第55回日本癌治療学会学術集会, Oct. 2017.
209.	Hiroki Teraoku, Tetsuya Ikemoto, Yuuma Wada, Shogo Oota, Yu Saitou, Shuichi Iwahashi, Satoru Imura, Yuji Morine, Mitsuo Shimada and Koichi Tsuneyama : 単純性嚢胞との鑑別に苦慮したnonmucinous cyctadenoma の1例, 第67回日本消化器画像診断研究会, Sep. 2017. (Keyword) 第67回日本消化器画像診断研究会
210.	Hiroki Teraoku, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Shogo Oota, Satoru Imura and Mitsuo Shimada : Nrf2-Keap1制御系を介したEpigallocatechin-3-gallate(EGCG)による膵島保護作用に関する検討, 第53回日本移植学会総会, Sep. 2017.
211.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Mitsuo Shimada : Treatment outcome for recurrent pancreatic cancer, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

消化器癌における化学療法耐性機序解明に関する研究 (Project/Area Number: 23K15451 )
免疫チェックポイント阻害薬治療時おけるhyperprogressinのメカニズムの解明 (Project/Area Number: 23K08091 )
脂肪幹細胞由来Schwann様細胞の骨盤内臓神経再生促進効果に関する研究 (Project/Area Number: 22K08713 )
Effect of duodenal-jejunal bypass on diabetes in the early postoperative period (Project/Area Number: 21K20953 )
Search by Researcher Number (80773944)

Designated Assistant Professor : Wada, Yuuma

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)